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LEARNING THE HARD WAY:
L-TRYPTOPHAN, THE FDA, AND THE
REGULATION OF AMINO ACIDS
I sit before you helpless, broke, alone and in unyielding,
relentless pain .... For those who have died and for those
of us who live with cloudy futures, the lack of action is too
little, too late. We have needed help with our orphan dis-
ease. We need help now .... The U.S. Government is
totally ineffective, and each agonizing day we grow more
fragile.
For those who appear to be in remission, we rejoice. But
we cannot say with certainty that anyone is cured as long as
the exact cause and cure is not found.
For many of us, it is too late. We want life again.'
- Frances L. Thompson, EMS Victim
INTRODUCTION
Reports of a mysterious, crippling illness surfaced in New
Mexico during October, 1989.2 Severe muscle pain, a marked
thickening of the skin, fatigue, dyspnea,3 and blood counts4
well out of the normal range inflicted previously healthy
people.5 The mystery illness, eosinophilia-myalgia syndrome
(EMS), today numbers over 1500 cases and thirty-eight con-
'FDA's Regulation of the Dietary Supplement L-tryptophan, 1991: Hearing
Before the Human Resources and Intergovernmental Relations Subcommittee
of the House Committee on Government Operations, 102d Cong., 1st Sess. 26
[hereinafter Hearing] (statement of Frances L. Thompson, EMS Victim).
2 Mary L. Kamb et al., Eosinophilia-Myalgia Syndrome in L-tryptophan-
Exposed Patients, 267 JAMA 77, 77 (1992).
' Dyspnea is an "air hunger resulting in labored or difficult breathing,
sometimes accompanied by pain." TABER'S CYCLOPEDIC MEDICAL DICTIONARY
547 (Clayton L. Thomas ed., 16th ed. 1989) [hereinafter TABER'S].
4 Specifically, afflicted people had abnormal eosinophil counts. The EMS
Story, FIBROMYALGiA NETWORK: NEWSLETTER FOR FimROMYALGiA, FIBROSI-
TIs/CFS SUPPORT GROUPS (Bakersfield, Cal.), Oct. 1993, at 5. An eosinophil
is a type of white blood cell which "constitute[s] 1% to 3% of [the] white blood
cell count." TABER'S, supra note 3, at 1020.
' The EMS Stoy, supra note 4, at 5.
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firmed deaths.6 Many of those who survive exist in states of
incapacitating pain and disability.'
How did this disease come about? Although initially a
baffling puzzle, researchers now understand that EMS was
caused by contaminated L-tryptophan.8 L-tryptophan is an
amino acid which was sold as an over-the-counter dietary
supplement in health food stores and pharmacies. Manufactur-
ers advertised L-tryptophan as a "natural" sleep aid, a remedy
for premenstrual syndrome, and a cure for depression? In
reality, it was neither natural nor approved by the FDA for
these proposed uses.' ° Yet it was readily available.
The EMS epidemic brought about an awakening in the U.S.
Government. The regulation of dietary supplements became a
hot topic. Members of Congress introduced three bills in 1993
aimed at altering the standards for regulating dietary supple-
ments in the Food, Drug, and Cosmetic Act."
This Note examines the regulatory scheme necessary to
prevent future public health threats related to dietary supple-
ments, using the L-tryptophan-related EMS outbreak as an
' Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (1993).
Although the official number of cases reported is set at 1500, the National
EMS Support Group alleges that EMS afflicts more than 5000 people. See
Louis Jacobson, Washington Update, 25 NAT'L J. 1237, 1237 (1993).
The EMS Story, supra note 4, at 5.
8 Laurence Slutsker et al., Eosinophilia-Myalgia Syndrome Associated with
Exposure to Tryptophan from a Single Manufacturer, 264 JAMA 213, 215
(1993).
9 David L. Wilson, Tracking Down a Killer, 22 NAT'L J. 2491, 2491 (1990).
10 Malcolm Gladwell, '72 Diet-Pill Ban Ignored Until Recent Deaths, WASH.
POST, Sept. 5, 1990, at Al.
Tryptophan in a bottle is not a nutritional supplement. Tryptophan
in dietary protein is an important nutrient. When you have it in
protein it comes along with 21 other amino acids and you need the
pattern, all of them, in order to utilize them to make your own
protein.
When you take pure tryptophan in pills or in a bottle, it's not
natural. Never in man's evolutionary history did he or she take an
individual amino acid of that sort. It doesn't happen; it's not
natural.
Hearing, supra note 1, at 71 (statement of Richard J. Wurtman, M.D.,
Professor of Basic Neuroscience and Director, Clinical Research Center,
Massachusetts Institute of Technology).
11 H.R. 1709, 103d Cong., 1st Sess. (1993); H.R. 2923, 103d Cong., 1st Sess.
(1993); H.R. 509, 103d Cong., 1st Sess. (1993).
REGULATION OF AMINO ACIDS
example. Part I discusses the history of government regulation
of amino acids and other dietary supplements. Part II docu-
ments the EMS outbreak and how its cause - contaminated
L-tryptophan - was discovered. Part III discusses pertinent
aspects of proposed regulatory frameworks for amino acid
dietary supplements and analyzes their efficacy. Part IV exam-
ines the Canadian framework for the regulation of food and
drugs, which effectively insulated Canada from an outbreak of
L-tryptophan related EMS. Part V proposes several alternatives
for the effective regulation of amino acid dietary supplements.
I. BACKGROUND
A. A BRIEF OVERVIEW OF AMINO ACIDS
Amino acids - components of proteins - are one of the
seven materials necessary for animal life.' 2 In their natural
form, amino acids result from the breakdown of proteins in the
digestive process.'" Enzymes first break proteins into polypep-
tides, 4 the basic structural components of protein mol-
ecules.' 5 Eventually, through interaction with additional en-
zymes, 6 the polypeptides break down into dipeptides and
finally amino acids.'7 Amino acids then diffuse through the
mucous membranes of the intestine and into the body to carry
out their functions.'8
The body uses amino acids to produce hormones such as
insulin, to produce enzymes, and to produce antibodies.'9 In
12 PAUL B. WEISZ, THE SCIENCE OF BIOLOGY 447 (3d ed. 1967). The other
necessary materials are water, minerals, organic carbon, organic nitrogen,
vitamins, and essential fatty acids. Id.
'
3Id. at 454.
14 Id. These enzymes (trypsin, chymotrypsin, and pepsin) are proteinases.
Id. A proteinase is "an enzyme that catalyzes the breakdown of native
proteins." TABER'S, supra note 3, at 1500.
16 WEISZ, supra note 12, at 846.
16 These enzymes are called peptidases. Id. A peptidase is "an enzyme
promoting the liberation of individual amino acids from a peptide, that is, an
amino acid complex smaller than a whole protein." Id.
7Id. at 454.
18 Id. at 456-57.
19 THE COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
COMPLETE HOME MEDICAL GUIDE 306 (Donald F. Tapley et al. eds., rev. ed.
19941 385
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nature, eighty amino acids exist; the human body has the
capacity to produce all but eleven of these.2 ° The human diet
must include all eleven of these "essential" amino acids: histi-
dine, isoleucine, leucine, lysine, methionine, cystine, phenylala-
nine, tyrosine, threonine, tryptophan, and valine.2' The essen-
tial amino acids exist in foods as varied as milk, meat, egg
whites, grains, and legumes."
Amino acid deficiencies are rare in the United States
because Americans consume excessive amounts of protein.23
Although health food stores carry protein and amino acid
supplements, doctors state that amino acid supplements yield
no proven benefits and can lead to nutritional imbalances.24
The amino acids that consumers purchase in health food stores
and pharmacies are not food proteins broken down into their
component amino acids; instead, health food stores sell single
amino acids isolated in a way not found in nature." Amino
acid supplements are available in pills and powders, and some
are genetically engineered."
1989) [hereinafter COMPLETE HOME MEDICAL GUIDE].
20 See TABER'S, supra note 3, at 74.
21 Id. at 74. The nonessential amino acids (which can be produced by the
body) are alanine, aspartic acid, arginine, citruline, glutamic acid, glycine,
hydroxyglutamic acid, hydroxyproline, norleucine, proline, and serine. Id.
22 COMPLETE HOME MEDICAL GUIDE, supra note 19, at 306.
23 Id.
I would hasten to say that there is not a single person in America
who is tryptophan deficient. It doesn't happen that you get isolated
amino acid deficiencies.
Hearing, supra note 1, at 71 (statement of Richard J. Wurtman, M.D.,
Professor of Basic Neuroscience and Director, Clinical Research Center,
Massachusetts Institute of Technology).
24 COMPLETE HOME MEDICAL GUIDE, supra note 19, at 307. Genetic
anomalies in amino acid metabolism are possible. These deficiencies may be
in transport (in the renal tubule or gastrointestinal mucosa) or catabolic. THE
MERCK MANUAL OF DIAGNOsIs AND THERAPY 2235 (Robert Berkow et al. eds.,
1992). One of the best known catabolic diseases is phenylketonuria, in which
the body does not correctly excrete excess phenylalanine. If treated through
regulation of phenylalanine intake, phenylketonurics may follow the normal
development pattern. Children inflicted with phenylketonuria may follow a
normal growth and development pattern. If left untreated, phenylketonuria
leads to often severe mental retardation. Approximately one in every 16,000
persons is afflicted. Id. at 2235-41.
' See Hearing, supra note 1, at 71.
2'6 L-tryptophan was engineered by a process called fermentation. Edward
1994]
Tryptophan , one of the essential amino acids, occurs
naturally in cottage cheese, milk, turkey, bananas, meat, dried
dates, peanuts, and all other protein-rich foods. 28 Once ingest-
ed, the body converts tryptophan into serotonin,29 a neuro-
transmitter "thought to be involved in neural mechanisms
important in sleep and sensory perception. ''30  Studies have
shown that tryptophan induces sleep3' without the side effects
A. Belongia et al., An Investigation of the Cause of Eosinophilia-Myalgia
Syndrome Associated with Tryptophan Use, 323 NEW ENG. J. MED. 357, 360
(1990).
27 For purposes of clarity the term "tryptophan" is used when referring to
the amino acid in general terms. "L-tryptophan" is used when discussing the
manufactured version of the amino acid.
28 EARL MINDELL, UNSAFE AT ANY MEAL 190 (1987).
Belongia et al., supra note 26, at 357. Serotonin is a neurotransmitter
- a biochemical used to relay nerve impulses. The breakdown route of trypto-
phan follows two paths. One pathway is the kynurenine pathway, the other
the serotonin pathway. See Hearing, supra note 1, at 66 (statement of Esther
M. Sternberg, M.D., Chief, Unit on Neuroendocrine Immunology and Behavior,
Clinical Neuroendocrinology Branch, National Institute of Mental Health,
Alcohol, Drug Abuse and Mental Health Administration). One kynurenine,
quinolinic acid, is a neurotoxin linked to Huntington's Disease, temporal lobe
epilepsy, hepatic encephalopathy and coma. Id. at 126-27 (letter of Andrew
Freese et al. to Frank Young (Feb. 1, 1988)). A large neutral amino acid
transport system controls tryptophan access across the blood-brain barrier.
Therefore, when tryptophan is ingested alone, absent competitive amino acids,
the level of tryptophan in the brain increases, as well as the amount of
serotonin and kynurenines in the body. Id. at 126 (letter of Andrew Freese to
Frank Young (Feb. 1, 1988)).
" TABER'S, supra note 3, at 1665.
"
1See Ernest Hartmann et al., Hypnotic Effects of L-tryptophan, 31
ARCHivES OF GEN. PSYCHIATRY 394, 394 (1974) (determining that L-trypto-
phan, administered in doses as small as one gram, significantly decreased
sleep latency, and that those who took L-tryptophan presented no more side
effects than those who took a placebo); see also C.F.P. George et al., The Effect
of L-tryptophan on Daytime Sleep Latency in Normals: Correlation with Blood
Levels, 12 SLEEP 345, 349 (1989) (finding that L-tryptophan ingestion reduces
sleep latency); Cheryl L. Spinweber et al., L-tryptophan: Effects on Daytime
Sleep Latency and the Waking EEG, 55 ELECTROENCEPHALOGRAPHY & CLINI-
CAL NEUROPHYsIOLOGY 652, 660 (1983) (finding that "L-tryptophan is an
effective daytime hypnotic which can facilitate sleep onset at clock times which
do not coincide with biological sleep times"); Arthur Yuwiler et al., Short-Term
and Repetitive Administration of Oral Tryptophan in Normal Men, 38 AR-
CHivES GEN. PsYCHIATRY 619, 619 (1981) (finding that all research subjects
became drowsy 20 to 30 minutes after tryptophan ingestion); cf William J.
Griffiths et al., Tryptophan and Sleep in Young Adults, 9 PSYCHOPHYSIOLOGY
345, 345 (1972) (finding that while a 7.5 gram dose of L-tryptophan reduces
REGULATION OF AMINO ACIDS 387
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of sleeping pills.32 Although health manuals discuss the bene-
fits of tryptophan and its breakdown product, they advise that
one should exercise care before ingesting L-tryptophan.3 For
example, The Complete Book of Vitamins and Minerals for
Health states that tryptophan could be useful for depression,
insomnia, pain relief, and maybe even mania, but adds that
"[s]ince relatively little is known about the safety of amino
acids, be guided by your physician in the medical use of any of
these substances.
34
Why the caution? Although studies have shown amino
acids may provide health benefits, 5 scientists have associated
health dangers with their unfettered use. 5
B. REGULATORY HISTORY OF L-TRYPTOPHAN AND OTHER
AMINO ACIDS
In 1945, the Food and Drug Administration issued a Trade
Correspondence stating that any food with added amino acids
must be labelled as being intended for special dietary use.37
the wakefulness time and increased amount of slow wave sleep in experi-
mental subjects, a 12 gram dose decreased sleep latency but increased REM
sleep). But see J. Gila Lindsley et al., Selectivity in Response to L-tryptophan
Among Insomniac Subjects: A Preliminary Report, 6 SLEEP 247, 253 (1983)
(finding that insomniacs can be divided into groups based on tryptophan
response or lack thereof); A.N. Nicholson & Barbara M. Stone, L-tryptophan
and Sleep in Healthy Men, 47 ELECTROENCEPHALOGRAPHY & CLINICAL
NEUROPHYSIOLOGY 539, 544 (1979) (finding it impossible to establish the
efficacy of L-tryptophan on nighttime sleep as compared to a placebo).
32 Sleeping pills not only cause sleep after ingestion but continue to cause
effects the following day. "At least, L-tryptophan bears a relationship to brain
serotonin and to probable natural sleep mechanisms, whereas most standard
hypnotic agents are general anesthetics used in small doses." Hartmann,
supra note 31, at 397.
3 JUDITH J. WURTMAN, MANAGING YOUR MIND AND MOOD THROUGH FOOD
21-23 (1986); see also THE COMPLETE BOOK OF VITAMINS AND MINERALS FOR
HEALTH 235 (Sharon Faelten et al. eds., 1988) [hereinafter COMPLETE BOOK OF
VITAMINS].
34 COMPLETE BOOK OF VITAMINS, supra note 33, at 236.
' See generally Hartmann et al., supra note 31; Yuwiler et al., supra note
31; Spinweber, supra note 31.
36 See infra notes 46-51, 86-92 and accompanying text.
3' FDA Trade Correspondence No. 2A (Nov. 5, 1945), in VINCENT A.
KLEINFELD & CHARLES W. DUNN, FEDERAL FOOD, DRUG AND COSMETIC ACT:
JUDICIAL AND ADMINISTRATIVE RECORD, 1938-1949, at 748 (1950).
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The Correspondence also stated that certain amino acid prepa-
rations for oral ingestion might be subject to regulation under
the drug provisions of the Federal Food, Drug, and Cosmetic
Act.3
8
Congress further regulated amino acids in 1958 by passing
the Food Additives Amendment.39 The Amendment included
a definition of "food additive:
The term "food additive" means any substance the
intended use of which results or may reasonably be
expected to result, directly or indirectly, in its becoming
a component or otherwise affecting the characteristics
of any food (including any substance intended for use in
producing, manufacturing, packing, processing, prepar-
ing, treating, packaging, transporting, or holding food;
and including any source of radiation intended for any
such use), if such substance is not generally recognized,
among experts qualified by scientific training and
experience to evaluate its safety, as having been ade-
quately shown through scientific procedures (or, in the
case of a substance used in food prior to January 1,
1958 through either scientific procedures or experience
based on common use in food) to be safe under the
conditions of its intended use.40
The Amendment also contained a provision allowing manu-
facturers to petition to establish the safety of a food additive.4
Absent a petition, a food additive is considered to be unsafe
unless an exemption exists covering the additive or a regulation
establishing its safety is promulgated.42 To establish safety,
the petitioner must file: (1) the name of and information about
the food additive and its composition; (2) the conditions for
' "Amino acid preparations offered for parenteral [other than oral] use fall
in the category of new drugs." Id. at 749.
" Food Additives Amendment of 1958, Pub. L. No. 85-929, 72 Stat. 1784
(codified as amended at 21 U.S.C. §§ 301, 321, 331, 342, 346, 348, 451 (1988)).
40 Id. (codified as amended at 21 U.S.C. § 321(s)(1988)). For more informa-
tion regarding the generally recognized as safe (GRAS) requirement, see
generally Frederick H. Degnan, Rethinking the Applicability and Usefulness
of the GRAS Concept, 46 FOOD DRUG CosM. L.J. 553 (1991).
"I Food Additives Amendment of 1958, Pub. L. No. 85-929, 72 Stat. 1784,
1785 (codified as amended at 21 U.S.C. § 348(b)(1) (1988)).
42Id. (codified as amended at 21 U.S.C. § 348(a) (1988)).
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which its use would be proposed and for which it would be
labelled; (3) the technical effect or physical effect the additive
would be intended to produce and the quantity required to
produce that effect; (4) a description of practicable methods for
determining the quantity of additives in the food; and (5) re-
ports of investigations on the safety of the additive for use.4"
No petitions were filed for L-tryptophan between 1958 and
1960.
In 1961, based on information available at the time, the
Food and Drug Administration listed L-tryptophan and other
amino acids as "generally recognized as safe (GRAS)"44 as
defined under the Food Additives Amendment. According to the
Amendment, "[g]eneral recognition of safety requires common
knowledge about the substance throughout the scientific com-
munity knowledgeable about the safety of substances directly or
indirectly added to food."45 Although the FDA listed L-trypto-
phan as GRAS for use as a dietary supplement in 1961, scientif-
ic evidence mounted throughout the 1960s that L-tryptophan
and other amino acids were not as safe as initially presumed.
Scientific studies found that the injection of serotonin, 4 a
neurotransmitter which is derived from tryptophan, would lead
to skin and joint fibrosis.4 ' Researchers expressed concerns
about potential carcinogenicity of L-tryptophan because trypto-
phan metabolites 4' and aromatic bladder carcinogens have
" Id. (codified as amended at 21 U.S.C. § 348(b)(2) (1988)).
4 21 C.F.R. § 121.101(d)(5) (1970).
45 Id.
46 L-tryptophan breaks down into serotonin. See Hearing, supra note 1, at
66 (testimony of Esther M. Sternberg, M.D., Chief, Unit on Neuroendocrine
Immunology and Behavior, Clinical Neuroendocrinology Branch, National
Institute of Mental Health, Alcohol, Drug Abuse, and Mental Health Ad-
ministration, Figure 1).
47 See O.B. Gum et al., Effect of Intra-articular Serotonin and Other
Amines on Connective Tissue Proliferation of Rabbit Joints, 3 ARTHRITIs &
RHEUMATISM 477, 477 (1960) (finding that serotonin can cause proliferation of
connective tissue and enlargement of knee joints in rabbits when combined
with the monoamine oxidase inhibitor iproniazid); Richard A. McDonald et al.,
Dermal Fibrosis Following Subcutaneous Injections of Serotonin Creatinine
Sulphate, 97 PROC. SoC'Y EXPERIMENTAL BIOLOGY 334, 335 (1958) (finding
that after 30 days rats receiving serotonin injections lost most of their hair in
the regions of the injections and experienced visible thickening of their skin).
41 Metabolites are any product of metabolism, which is the sum of all
physical and chemical changes that take place within an organism. See
TABER'S, supra note 3, at 115-16.
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similar chemical structures.49 Studies raised the possibility of
hepatotoxicity ° after scientists recorded liver changes in rats
fed L-tryptophan. 51
Coincident with these concerns about L-tryptophan's safety,
researchers found potential medicinal uses for L-tryptophan.
Dr. Richard Wurtman of the Massachusetts Institute of Tech-
nology's Clinical Research Center found that blood tryptophan
levels control serotonin levels, affecting sleep, mood, and appe-
tite.52 Based on this discovery, Wurtman suggested that
L-tryptophan may have properties making it useful to remedy
insomnia, control appetite, regulate mood, and act as a painkill-
er.53 Thus, after the FDA's 1961 designation of L-tryptophan
as GRAS, research suggested new uses for L-tryptophan while,
at the same time, other studies questioned its safety.
On April 6, 1972, the FDA took action in response to the
mounting evidence that amino acid supplements were unsafe,
proposing to remove amino acids from the list of nutrients or
49 Hearing, supra note 1, at 125 (letter from Andrew Freese et al. to Frank
Young (Feb. 1, 1988)); see also W.F. Dunning et al., The Effect of Added
Dietary Tryptophane on the Occurrence of2-Acetylaminofluorene-induced Liver
and Bladder Cancer in Rats, 10 CANCER REs. 454,454 (1950) (concluding that
tryptophan dietary supplements enhanced carcinogenic effects of 2-fluor-
eulacetamide in the bladder- of rats); Osamu Yoshida et al., Relationship
Between Tryptophan Metabolism and Heterotrophic Recurrences of Human
Urinary Bladder Tumors, 25 CANCER 773, 778 (1970) (showing a correlation
between the recurrence of bladder cancer and elevated tryptophan levels).
50 Hepatotoxic is defined as "toxic to the liver." TABER'S, supra note 3, at
820.
51 See Herschel Sidransky et al., Effect of Tryptophan on Polyribosomes and
Protein Synthesis in Liver, 24 AM. J. CLINICAL NUTRITION 779, 783 (1971)
(finding a shift toward a heavier aggregate of hepatic polyribosomes and an
increase in in vitro protein synthesis from tryptophan use); Michael E. Trulson
& H. Wayne Sampson, Ultrastructural Changes in the Liver Following
L-tryptophan Ingestion in Rats, 116 J. NUTRITION 1109, 1114 (1986) (finding
that high doses of L-tryptophan, within a range used by humans for sleep
induction, produce abnormal morphology of the liver in rats).
2 Hearing, supra note 1, at 70 (statement of Richard J. Wurtman, M.D.,
Professor of Basic Neuroscience and Director, Clinical Research Center,
Massachusetts Institute of Technology).
I Id. In 1991, Dr. Wurtman, speaking in front of the House Subcommittee
researching L-tryptophan, noted that his research led to the determination
that L-tryptophan could have pharmacological uses in the treatment or
mitigation of bodily dysfunctions. However, he did not believe that L-tryp-
tophan had any use as a dietary or nutritional supplement. See id. at 71-72.
1994] 391
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dietary supplements "GRAS without further limitation."'" The
FDA took the stance that the presence of amino acids in a
particular food in protein form does not imply that they are safe
to add in their solitary form.55 When amino acids are present
in such imbalanced and artificially high quantities, they can
produce toxic effects, an unbalanced protein, s or an amino
acid imbalance in the diet.57 The FDA further acknowledged
the growing body of evidence that amino acids were not harm-
less:
Experimental animal studies have shown that the
adverse effects of these imbalances are suboptimal food
intake, growth retardation, and degeneration of certain'
organs which can lead to the animal's early death.
Excessive intakes of most of the nutritionally nonessen-
tial amino acids (for example tyrosine and glycine) will
produce undesirable biochemical and pathological
effects in animals. This indicates a potential health
risk in man if use is not limited.58
The FDA then promulgated new regulations aimed at
insuring the safe use of amino acids in foods.59 These new
regulations effectively removed L-tryptophan and other amino
acids from the GRAS list.60 The comments preceding the regu-
lation state that there is "no reason to permit amino acid sup-
plementation [of food] unless it will provide for a significant
improvement in the protein quality."'" Based on this regula-
tion, the FDA takes the position that the marketing of amino
acids - for example, L-tryptophan - as dietary supplements
has been illegal since 1973.2
' 37 Fed. Reg. 6,938, 6,939 (1972) (proposed Apr. 6, 1972).
55 Id. at 6,938.
56 An unbalanced protein is "one used inefficiently for growth." Id.
57 Id.
58 Id. at 6,938-39.
'9 38 Fed. Reg. 20,036 (1973).
ro See id. at 20,038.
61 Id. at 20,036.
2 Hearing, supra note 1, at 105 (statement of Douglas Archer, Deputy
Director of FDA Center for Food Safety and Applied Nutrition) ("[We wanted
to ... limit the approved food additive use of amino acids to foods that
contained naturally occurring, primarily intact protein that is considered a
REGULATION OF AMINO AcI3DS
The dietary supplement industry argues that the regula-
tions do not govern the use of L-tryptophan as a dietary supple-
ment.63 The industry relies on a statement in the 1972 propos-
al reporting that the regulations do not "cover the inclusion of
amino acids in foods which do not contain original intact pro-
tein,"' 4 and that "such uses will be the subject of separate
[regulatory] actions."65 The industry has therefore argued
that, although the 1973 regulations expressly granted GRAS
recognition to amino acids added to protein-containing foods, the
regulations did not affect the status of amino acids used in other
forms, such as free amino acids or those contained in dietary
supplements.66 Finally, the industry contends that because
amino acids are GRAS for certain uses as food substances, food
additive regulations do not apply.6"
In addition, FDA inadvertence provided the supplement
industry with an argument that amino acids were not food
additives under the regulations. From 1974 through 1976,
L-tryptophan was listed as a food additive in each year's Code
of Federal Regulations. 6 However, during the 1977 recodifica-
tion of its regulations, the FDA erroneously listed L-tryptophan
as a "nutrient/dietary supplement. '" 69 The supplement industry
has used this mistake as the basis for its argument that L-tryp-
tophan was not a food additive and therefore GRAS, even
though the recodification contained a blanket statement that all
changes were nonsubstantive in nature." The FDA corrected
the error in a notice published in the Federal Register on
October 28, 1977,7 ' but the damage was already done.
significant dietary source.").
6 Id. at 291 (letter from J.B. Cordaro, President of the Council for Respon-
sible Nutrition).
' 37 Fed. Reg. 6938, 6939 (1972) (proposed on April 6, 1972).
65 Id.
6 Hearings, supra note 1, at 275-76 (letter from Stanley Jacobson, Presi-
dent, National Nutritional Foods Association to Representative Ted Weiss
(July 17, 1991)).
67 Id. at 289-305 (letter from J.B. Cordaro, President, Council for Responsi-
ble Nutrition to Congressman Ted Weiss (July 17, 1991)).
6 See 21 C.F.R. §§ 121.101(d)(5), 121.1002 (1974); 21 C.F.R. §§ 121.101
(d)(5), 121.1002 (1975); 21 C.F.R. §§ 121.101(d)(5), 121.1002 (1976).
69 21 C.F.R. § 182.5915 (1977).
'0 42 Fed. Reg. 14,306, 14,306 (1977).
"' 42 Fed. Reg. 56,723, 56,728-29 (1977).
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At the House Subcommittee hearing, a memorandum from
the Office of the General Counsel of the Department of Health
and Human Services' Food and Drug Division detailed two
separate instances of the FDA's failed attempts to enforce this
correction. 2 The FDA first seized an L-tryptophan formula-
tion labelled as a dietary supplement on the grounds that it was
an unapproved food additive, sold in violation of food additive
regulations. 3 The manufacturer sued the FDA challenging the
legality of the seizure, arguing that it could rely on the pub-
lished regulation until officially changed. Although this seizure
occurred prior to the issuance of the correction, the FDA argued
that the seizure was valid because it recognized the printing
error and had initiated efforts to publish a retraction. 4 The
court held that the seizure was illegal under the regulations as
published,75 impeding the FDA's attempt to regulate amino
acids as a food additive.
In 1977, prior to the October correction, the FDA imple-
mented a second seizure of a dietary supplement formulation of
L-tryptophan.76 The FDA continued to insist that such a sei-
zure was valid under the regulations." Before trial of the
second siezure's legality, the district court issued a broad state-
ment indicating that the FDA may not have the authority to
regulate the combination of any food ingredients, which sur-
prised FDA attorneys.' Sure that they would lose the case,
their lawyers convinced the FDA to settle it. 9
As a result of these two court losses - and the concomitant
expenses - the FDA stopped attempting to regulate the mar-
keting of amino acids to consumers.80 The 1976 Proxmire
72 Hearing, supra note 1, at 155 (note from Mary Pendergast, General
Counsel, Department of Health and Human Services).
73 Id.
74 Id.
" Id. (citing United States v. An Article of Food ... Schiff Natural
L-tryptophane, No. 77-768 (D. N.J. Nov. 30, 1977)).
76 Id. at 156.
77 Id. (the regulation at issue was 21 C.F.R. § 172.320).
71 Id. at 158 (citing United States v. An Article of Food... L-tryptophan,
No. 77-768 (D. N.J. Jan. 23, 1979)).
79 Id. at 158-59.
" Id. at 106 (statement of Douglas Archer, Deputy Director of FDA Center
for Food Safety and Applied Nutrition).
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Amendment81 pushed the FDA further in the direction of non-
regulation. The Amendment forbade the FDA from limiting the
potency of vitamin and mineral supplements.82 Previously, the
FDA proposed a reclassification of high dosages of Vitamins A
and D, arguing that high dosages are only appropriate for drug
usage.83  The Proxmire Amendment prevented this proposed
reclassification.' The FDA viewed the Amendment as a warn-
ing that Congress would not tolerate the regulation of supple-
ment products unless they posed specific and immediate health
danger.8
5
Throughout the 1980s, the FDA turned its attention to
other matters despite mounting evidence that ingestion of free
amino acids could have deleterious health effects.86 In 1980,
L-5-hydroxytryptophan, a drug very similar to L-tryptophan,
was found to cause a scleroderma-like illness.8 Other studies
showed that quinolinic acid, an intermediary in the metabolism
of L-tryptophan, was linked with Huntington's Disease, 8 he-
8' 21 U.S.C. §.350 (1976).
82 See id. § 350(a)(1)(A)-(C).
83 Hearing, supra note 1, at 171 (memorandum from Margaret Jane Porter,
Chief Counsel of the Department of Health and Human Services).
8 Id.
' See id. at 105 (statement of Douglas Archer, Deputy Director of the FDA
Center for Food Safety and Applied Nutrition). A more recent FDA opinion,
subsequent to the L-tryptophan eosinophilia-myalgia syndrome outbreak,
digputes the FDA's original stance. A 1989 memo from the Chief Counsel of
the Department of Health and Human Services stated that "[tihe Proxmire
Amendment has no relevance, however, to what the agency would be doing
with respect to L-tryptophan. The Proxmire Amendment did not change the
requirements that a substance used in food must be either GRAS, prior-
sanctioned, or an approved food additive." Id. at 171 (memorandum from
Margaret Jane Porter).
See, e.g., Michael Castleman, The Enemy Within, CAL. LAW., Mar. 1993,
at 44 (recounting the slow regulatory response and the alleged cover up by the
FDA of the dangers of silicon breast implants; from the initial disclosure of the
implants' autoimmune effects in 1982, to the resulting flood of lawsuits and
plaintiffs' awards during which the FDA remained ineffective, to the eventual
moratorium on implant use in 1992).
87 Esther M. Sternberg et al., Development of a Scleroderma-like Illness
During Therapy with L-5-hydroxytryptophan and Carbidopa, 303 NEW ENG. J.
MED 782, 782 (1980). Scleroderma is defined as a chronic disease which
causes hardening of the skin and certain major organs of the human body.
TABER'S, supra note 3, at 1644.
' M. Flint Beal et al., Replication of the Neurochemical Characteristics of
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patic encephalopathy, s9 and coma. °  Numerous cases ap-
peared in which L-tryptophan, in combination with other phar-
maceuticals, produced toxic effects.9 Additionally, the amino
acid phenylalanine - widely used in diet soft drinks and in pill
form - also became suspect.92
Huntington's Disease by Quinolinic Acid, 321 NATURE 168, 169 (1986) (demon-
strating that quinolinic acid lesions closely resemble lesions caused by
Huntington's Disease, and suggesting that quinolinic acid or a similar com-
pound could be responsible for the neuronal degenerations characteristic of the
disease). Huntington's Disease is characterized as an inherited disease
causing involuntary movements and progressive dementia. TABER'S, supra
note 3, at 846.
" Hepatic encephalopathy, also called hepatic coma, is "impaired central
nervous system function due to liver disease." TABER'S, supra note 3, at 815-
16.
90 F. Moroni et al., Increase in the Content of Quinolinic Acid in Cerebrospi-
nal Fluid and Frontal Cortex of Patients with Hepatic Failure, 47 J. NEURO-
CHEMISTRY 1667, 1668 (1986) (reporting an increased content of quinolinic acid
in the frontal cortex of patients who died from hepatic coma, and extending
the previous observations of quinolinic acid in the brain of rats as models of
hepatic encephalopathy to humans); see also G. Curzon et al., Plasma and
Brain Tryptophan Changes in Experimental Acute Hepatic Failure, 21 J.
NEUROCHEMISTRY 137, 137 (1973) (finding abnormally high tryptophan levels
in the brain of human subjects with hepatic coma); F. Moroni et al., Content
of Quinolinic Acid and of Other Tryptophan Metabolites Increases in Brain
Regions of Rats Used as Experimental Models of Hepatic Encephalopathy, 46
J. NEUROCHEMISTRY 869, 869 (1986) (finding increased levels of tryptophan in
the brains of experimental rats used as models of hepatic encephalopathy).
9' See W. Steiner & R. Fontaine, Toxic Reaction Following the Combined
Administration of Fluoxetine and L-tryptophan: Five Case Reports, 21
BIOLOGICAL PSYCHIATRY 1067, 1067 (1986) (reporting the occurrence of a toxic
reaction in all five cases in which L-tryptophan was combined with fluoxetine
in the treatment of affective of obsessive-compulsive disorders); A.B. Levy et
al., Myoclonus, Hyperreflexia, and Diaphoresis in Patients on Phenelzine-
Tryptophan Combination Treatment, 30 CAN. J. PSYCHIATRY 434, 434 (1985)
(discussing the toxicity and resulting physical effects of the combination of
L-tryptophan and monoamine oxidase inhibitors in the treatment of depres-
sion).
92 People with phenylketonuria must maintain a low-phenylalanine diet to
prevent mental retardation. Annie Prince, Patterns of Phenylalanine Metabo-
lites, Vitamin B6 Status and Learning Disabilities in Phenylketonuria Chil-
dren: Modeling for Diet Criteria, in DIETARY PHENYLALANINE AND BRAIN
FUNCTION 244, 245 (Richard J. Wurtman & Eva Ritter-Walker eds., 1988); see
also Harvey L. Levy & Susan E. Waisbren, Effects of Untreated Maternal
Phenylketonuria and Hyperphenylalaninemia on the Fetus, 309 NEW ENG. J.
MED. 1269, 1269 (1983) (finding that the failure to maintain a low-phenyl-
alanine diet by women with maternal phenylketonuria results in mental
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During this same period of time, the dietary supplement
industry grew at an astonishing pace to become a four billion
dollar industry.93 The supplement industry also became more
bold, advertising supplements with claims that were more
pharmaceutical than nutritive in nature. For example, the FDA
received an anonymous package of advertisements for a variety
of L-tryptophan formulations9 4 which contained claims such as:
* [L-tryptophan is] an essential amino acid that works in
the brain to make 'Serotonin' a natural tranquilizer
substance that has been found to be useful as an aid for
relieving depression and possibly helping to induce
relaxation;95
* [L-tryptophan] relieves fatigue, wards off overexertion,
prevents nervousness, and mental sluggishness;9"
* [Tryptolyn (a combination of tryptophan and l ysine)]
reduc[es] plasma cholesterol and triglyceride levels,
heart attacks, strokes, atherosclerosis, arteriosclerosis,
and enlarged prostate glands;97
retardation or other birth defects in their offspring).
Dr. Richard J. Wurtman, Professor of Basic Neuroscience and Director,
Clinical Research Center, Massachusetts Institute of Technology, has pub-
lished nearly 400 articles on amino acids. According to him, phenylalanine
should not be on the market:
There is never, as far as I can tell, a reason ever for anyone to take
phenylalanine. There are about 4 million people out there who do
not know it, but their livers are not adequate at metabolizing
phenylalanine. And we know that phenylalanine can be directly
toxic to the brain .... So there's never a reason for selling phenyl-
alanine, but its sold out there right now.
Hearing, supra note 1, at 72-73.
" Senate Witnesses Say Process Needed to Balance Dietary Supplement
Issue, DAILY REP. FOR EXECUTIVES, Oct. 22, 1990, at 203.
' Hearings, supra note 1, at 174 (memo from Mary K. Pendergast, General
Counsel of the Department of Health and Human Services).
95 Id. at 175-76.
9 Id. at 176-77.
9 7 Id. at 177.
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0 [Tryptophan can be used for] dementia, insomnia,
senility, hallucination, depression, heart disease, and
carbohydrate craving.9"
Even today, magazine articles and manufacturers' promo-
tions make similar claims for other amino acids. L-arginine
allegedly improves the immune system.99 L-citrulline is "bene-
ficial in the presence of any illness, disease, traumatic injury or
wound."'' ° L-lysine allegedly helps "to control the frequency
and severity of herpes."'0 ' The list of asserted health benefits
of amino acids continues. 10
2
As the supplement industry brazenly advertised question-
able claims, the FDA - believing itself to be handcuffed by
current regulations - did nothing.' 3 Then, in October, 1989,
reports of a mysterious illness filtered out of New Mexico. 04
II. THE EOSINOPHILIA-MYALGIA OUTBREAK
AND ITS REPERCUSSIONS
On October 30, 1989, the New Mexico Department of Health
received reports that several people had developed a scarring
illness, characterized by elevated eosinophil counts and severe
myalgia. °5 The Centers for Disease Control and various state
health departments began an investigation after discovering
that all of the original New Mexico patients were L-tryptophan
98 Id.
99 Id. at 185.
'0o Id. at 186.
1t Id. at 188.
102 Products containing L-tryptophan continued to be advertised as late as
1992, three years after the FDA recall. Rossanne M. Philen et al., Survey of
Advertising for Nutritional Supplements in Health and Bodybuilding Maga-
zines, 268 JAMA 1008, 1009 (1992).
103 See Hearing, supra note 1, at 109-12 (statement of Dr. Douglas L.
Archer, Deputy Director, Center for Food Safety and Applied Nutrition)
(describing executive, judicial, and legislative atmosphere of the 1970s and
1980s); supra notes 75-81 and accompanying text.
"4 Leslie A. Swygert et al., Eosinophilia-Myalgia Syndrome: Results of
National Surveillance, 264 JAMA 1698, 1698 (1990).
"
5 Eosinophilia-Myalgia Syndrome - New Mexico, 38 MORBIDITY &
MORTALITY WKLY. REP. 765, 765 (1989).
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users."' On November 7, 1989, the first reports of a health
concern linked to L-tryptophan were filed in the FDA's New
Mexico field office.10 7  The FDA tracked the available data
over the following weekend and then acted quickly. On Novem-
ber 11, the FDA issued a warning to the public advising the
immediate discontinuation of L-tryptophan use. On November
17, the FDA requested a nationwide recall of all L-tryptophan
supplements of one hundred milligrams or more. On November
21, an importation alert was ordered, cutting off all importation
of L-tryptophan.'0 By December 6, 1989, cases were reported
in forty-eight states, the District of Columbia, and Puerto
Rico,0 9 with particular clusters of the illness in the Western
and Southwestern states, Minnesota, New Hampshire, New
York, and South Carolina."0 New reports of the illness,
named eosinophilia-myalgia syndrome (EMS), rapidly dropped
after the initial FDA recall."' On March 22, 1990, all prod-
ucts containing L-tryptophan were recalled.1
2
Although the number of cases dropped after the recall, the
misery of those suffering from EMS did not end. The Centers
for Disease Control adopted a surveillance definition for EMS,
requiring that, to be counted as suffering from EMS, a patient
display a systemic illness characterized by three conditions:
(1) severe myalgias,"3 (2) eosinophilia," 4 and (3) absence of
106
107 Hearing, supra note 1, at 97 (statement of Douglas Archer, Ph.D.,
Deputy Director, Center for Food, Safety and Applied Nutrition, FDA, U.S.
Department of Health and Human Services).
108 Id.
"09 Update: Eosinophilia Myalgia Syndrome Associated with L-trypto
phan - United States, 38 MoRB DrrY & MORTALITY WKLY. REP. 842, 842
(1989).
10 Swygert et al., supra note 104, at 1699. These states had EMS out-
breaks at a rate of 7.2 to 26.2 cases per million persons. Alaska, Arkansas,
Kansas, Louisiana, and Puerto Rico reported the lowest rates, with 0.2 to 1.9
cases per million. Id.
... Id. at 61 (statement of Esther M. Sternberg, M.D., Chief, Unit on
Neuroendocrine Immunology and Behavior, Clinical Neuroendocrinology
Branch, National Institute of Mental Health, Alcohol, Drug Abuse, and Mental
Health Administration). The epidemic peaked in November 1989. Id.
112 FOOD AND DRUG ADMINISTRATION, 90-15 FDA ENF. REP. 1, 1990 WL
262939 (FDA).
11 Myalgia is a tenderness or pain in the muscles. TABER'S, supra note 3,
at 1164.
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any infectious or neoplastic" 5 causes accounting for the eosino-
philia and myalgia." 6 However, EMS sufferers display a wide
variety of symptoms including fatigue, generalized weakness,
edema, rash, paresthesias, muscle cramps, extremity weakness,
and excessive hair loss.
117
EMS passes through two phases. In the acute phase, the
patient suffers from eosinophilia, fever, muscle aches, cough,
shortness of breath, pneumonia, skin swelling, skin rashes,"'
and - in some cases - paralysis of the muscles which control
breathing."9 The second, chronic phase includes symptoms
such as fatigue, muscle weakness, aches and cramping, joint
pain, scarred and tight skin, anxiety, depression, memory loss,
and menstrual problems, as well as nerve, heart, and lung dam-
age.1
20
Unfortunately, the majority of EMS cases do not resolve
themselves over time. Two years after the EMS outbreak,
although eighty percent of EMS cases showed some improve-
ment, over sixty percent of the patients had symptoms charac-
terized as moderately to extremely severe, and only ten percent
had completely recovered.' 2' As of June, 1993, thirty-eight
people had died of EMS - largely from heart problems and
paralysis of muscles surrounding the lungs - and the number
114 Eosinophilia is the presence of an unusual number of eosinophils in the
blood. Id. at 605.
115 A neoplasm is a new and abnormal formation of tissue as a tumor or
growth. Id. at 1190.
116 Eosinophilia Myalgia Syndrome and L-tryptophan Containing Prod-
ucts - New Mexico, Minnesota, Oregon, and New York, 1989, 38 MORBIDITY
AND MORTALITY WKLY. REP. 785, 787 (1989). The Centers for Disease Control
surveillance definition may have led to underreporting of L-tryptophan-related
EMS, due to the wide variations in symptoms suffered by the patients.
Underreporting of EMS Seen by CDC Doctors, 35 FOOD CHEMIcAL NEWS 36, 36
(1993).
117 Katrina Hedberg et al., Eosinophilia-Myalgia Syndrome: Natural
History in a Population-Based Cohort, 152 ARCHIVES INTERNAL MED. 1889,
1889 (1992).
118 Hearing, supra note 1, at 59 (statement of Esther M. Sternberg, M.D.,
Chief, Unit on Neuroendocrine Immunology and Behavior, Clinical Neuroendo-
crinology Branch, National Institute of Mental Health Alcohol, Drug Abuse,
and Mental Health Administration).




of people injured had climbed to 1500, although there could be
many more undiagnosed cases. '22
Once researchers linked L-tryptophan to EMS, they ques-
tioned what aspect of the L-tryptophan caused the EMS, and
why L-tryptophan-related EMS had not emerged earlier."
By the third week of November 1989, Dr. Gerald Gleich, a re-
searcher at the Mayo Clinic, and Dr. Michael Osterholm, epide-
miologist for the Minnesota Department of Health, united in an
effort to find the cause of EMS.'24 The Oregon Health Divi-
sion and the Centers for Disease Control began additional
studies. 25
In these studies, researchers traced the products through
the distribution chain to the manufacturers, who gave the
researchers the dates of production for each lot;126 six foreign
manufacturers had produced L-tryptophan imported to the
United States.'27 Statistical evidence showed a strong link
between manufacturer Showa Denko K.K. and the disease-
causing lots. 12 Using High-Performance Liquid Chromatogra-
phy, the researchers created a map of the chemical elements in
Showa Denko L-tryptophan. 129  Comparing the lots of non-
122 58 Fed. Reg. 33,690, 33,696 (1993).
12 Although the EMS epidemic peaked in the fall of 1989, running a course
from mid-summer 1989, to mid-winter 1990, there are documented cases of
EMS that did not occur in the time frame of the epidemic. One such case is
that of Paul L. Houts, who testified before the Subcommittee studying the
FDA regulation of L-tryptophan, that he became a victim of EMS in February
1988, having started taking L-tryptophan in the winter of 1987. Hearing,
supra note 1, at 30-31.
124 Bob Ehlert & Lewis Cope, Minnesota Mafia Tracked L-tryptophan
Impurity, STAR TRIBUNE (Minneapolis), July 23, 1990, at El.
125 Laurence Slutsker et al., Eosinophilia-Myalgia Syndrome Associated
with Exposure to Tryptophan from a Single Manufacturer, 264 JAMA 213, 214
(1990).
126 Id. at 358.
127 Edward M. Belongia et al., An Investigation of the Cause of the Eosino-
philia-Myalgia Syndrome Associated with Tryptophan Use, 323 NEW ENG. J.
MED. 357, 357-58 (1990).
"
2 Id. at 363. Showa Denko had a 70% market share in the production of
L-tryptophan. Bob Ehlert & Lewis Cope, L-Tryptophan's Role Revealed, But
Illness Lingers for Many, STAR TRIBUNE (Minneapolis), July 24, 1990, at El.
'" Belongia et al., supra note 127, at 362. HPLC creates a graph of the
chemical constituents of L-tryptophan. One hundred percent pure L-trypto-
phan would produce one large peak on the graph. Since no substance is 100%
pure, there are various smaller peaks on the graph indicating other present
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implicated Showa Denko L-tryptophan and the implicated lots,
a specific peak in the graph - named Peak E130 - was pres-
ent only in the EMS case-related L-tryptophan. 13 1
Showa Denko representatives revealed their complex
manufacturing process to the Minnesota researchers and invited
them to Japan to view the L-tryptophan production plant.13 2
Showa Denko produced L-tryptophan through a fermentation
process involving bacillus amyloiquefaciens.133  In December,
1988, Showa Denko began to use a new, genetically-altered
strain of bacillus amyloiquefaciens called Strain V, 34 and in
1989, reduced the amount of activated carbon in the purification
process by one-half. Between October, 1988, and June, 1989,
some batches bypassed a filter which removed heavier chemi-
cals. 3 5 These potentially contaminated batches went through
the purification process with other batches.' 36 Showa Denko
shipped the finished product to the United States. 137
Based on the evidence they gleaned from their research and
Showa Denko's records, the Minnesota researchers hypothesized
that the Peak E contaminant was a factor in causing EMS. 138
chemicals. The graphs vary depending upon the company producing L-trypto-
phan. This way, researchers may determine the manufacturing source of an
L-tryptophan pill. Ehlert & Cope, supra note 124, at El.
130 The Centers for Disease Control labeled this same point "Peak 97."
Analysis of L-tryptophan for the Etiology of Eosinophilia-Myalgia Syndrome,
39 MORBIDITY & MORTALITY WKLY. REP. 589, 589 (1990).
131 Belongia et al., supra note 127, at 360.
132 Ehlert & Cope, supra note 128, at El.
' Belongia et al., supra note 127, at 360.
134 Ehlert & Cope, supra note 128, at El.
135 Belongia et al., supra note 26, at 360.
136 Ehlert & Cope, supra note 128, at El.
137
These findings support a hypothesis that tryptophan containing an
unidentified chemical constituent contributes to the pathogenesis of
the eosinophilia-myalgia syndrome. Additional support for this
hypothesis is provided by the significant association between Peak
E... and manufacturing variables - the bacterial strain used and
the amount of powdered activated carbon used. The chemical
constituent represented by Peak E may cause the Eosinophilia-
Myalgia Syndrome or it may be a surrogate marker for another
unidentified substance which triggers the syndrome.
Belongia et al., supra note 127, at 362.
138 Although both Minnesota researchers state that Showa Denko was
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Researchers at the Oregon Health Division came to a similar
conclusion by comparing a group with EMS to a healthy control
group, both of which had ingested L-tryptophan.'39 The re-
searchers found that ninety-eight percent of EMS suffers had
taken products produced by one manufacturer - Showa Denko
- while the controls had taken products produced by many
different manufacturers. 40 The Oregon researchers further
determined that neither the average daily dose nor the length of
time a patient had been taking the L-tryptophan impacted the
timing of the symptoms' onset or the illness' severity.
141
Based on these findings, they hypothesized that a contaminant
in L-tryptophan formulation caused the EMS outbreak.'42
Dr. Esther M. Sternberg, at the National Institute for
Mental Health, developed similar findings. Dr. Sternberg deter-
mined rats fed case-related L-tryptophan developed scarring of
the connective tissue surrounding the muscles, while those fed
cooperative and wanted to find the cause of the EMS outbreak, other actions
taken by the company do not corroborate this; for example, the FDA curtailed
a plant inspection in May 1990, in which:
[tihe team encountered refusals to provide information, access to
records and areas routinely inspected and necessary to make a
comprehensive evaluation of the firm's operations and practices.
However, during the limited examination of the facility, numerous
structural defects and potential routes of contamination were noted,
but pursuit of these areas was not possible.
Hearing, supra note 1, at 251 (endorsement of Peter D. Smith). Plaintiffs'
attorneys have stated Showa Denko has been equally uncooperative in
subsequent litigation. In several cases, Showa Denko has argued it did not
have sufficient contacts with the U.S. to be brought into a U.S. court. In
DeMoss v. City Market the court adopted a stream of commerce theory, and
Showa Denko lost on that attempt. 762 F. Supp. 913, 917-19 (D. Utah 1991).
Stephen Fabbro, liaison to a California judge in California litigation, states
that Showa Denko's settlement strategy is based on delay, and Portland
attorney Gayle Troutwine states that Showa Denko makes depositions unduly
difficult by having them translated, although the deposees speak English.
L-Tryptophan: L is for Lucrative, THE RECORDER, Feb. 10, 1992, at 1.
Rebecca Weisman suggests that if a manufacturer does not exercise good faith
and diligence in turning over data, the FDA should implement economic
sanctions proportional to company assets. Rebecca Weisman, Reforms In Med-
ical Device Regulation, 23 GOLDEN GATE U. L. REV. 973, 995-96 (1993).
139 See Slutsker et al., supra note 125, at 213.
14o Id.
141 Id. at 214.
142 Id. at 215.
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purer L-tryptophan did not.14' Her research team believes
either one chemical or a chemical combination in the Showa
Denko L-tryptophan caused the syndrome.' To date, no one
has determined the exact chemical agent triggering EMS. 145
Once researchers determined the cause of the L-tryptophan
EMS epidemic, Congress took action. The House of Representa-
tives Human Resources and Intergovernmental Relations
Subcommittee of the Committee on Government Operations
held a hearing on the FDA's Regulation of L-tryptophan. 46
Representative Patsy Mink, the Committee Chairwoman, placed
the blame for the epidemic squarely at the feet of the FDA. 47
143 Hearings, supra note 1, at 56 (statement of Esther M. Sternberg, M.D.,
Chief, Unit on Neuroendocrine Immunology and Behavior, Clinical Neuroendo-
crinology Branch, National Institute of Mental Health, Alcohol, Drug Abuse,
and Mental Health Admninistration).
144 Id.
145 58 Fed. Reg. 33,690, 33,696 (1993). The Oregon researchers found three
ways a contaminant in L-tryptophan might cause EMS: (1) the contaminant
has "a direct toxic effect on the tissues," (2) "a contaminant might alter normal
tryptophan metabolism," and (3) "a contaminant might alter the bioavailability
of tryptophan, leading to abnormal gastrointestinal absorption of tryptophan
and/or bacterial luminal metabolism." Slutsker, supra note 125, at 217.
146 See Hearings, supra note 1, at 1.
147 Two other episodes indicate faulty FDA procedures.
DES. In 1947, the FDA approved the use of diethylstilbestrol (DES) to
prevent miscarriages on an experimental basis. DES was widely marketed
and prescribed throughout the 1950s and 1960s. However, the FDA's approval
was based on research which showed neither DES's safety nor its efficacy. In
1971, DES was linked to reproductive system cancers in the children of those
who had taken DES while pregnant. Only then did the FDA revoke approval
of the drug. DES had been on the market for twenty-four years. Rebecca
Weisman, Reforms in Medical Device Regulation: An Examination of the
Silicone Breast Implant Debacle, 23 GOLDEN GATE U. L. REV. 971, 982 (1993).
The Dalkon Shield. A.H. Robins introduced the Dalkon Shield in 1971.
In 1972, doctors reported to the FDA deaths caused by spontaneous septic
abortion related to the Dalkon Shield. The FDA did nothing. After threats by
the doctors to publish their findings in a medical journal, A.H. Robins agreed
to send a warning letter to doctors distributing the device. The FDA rejected
the letter, and when the head of the FDA unit regulating medical devices
requested that the FDA get an injunction prohibiting the further marketing of
the Dalkon Shield and recalling all of those on the market, the FDA refused.
Only in 1974 did the FDA request A.H. Robins to stop selling the Dalkon
Shield. Later trials revealed Robins had suppressed negative research
regarding the Dalkon Shield. Id. at 984.
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In her closing statement, Representative Mink focused on the
FDA's inaction:
Throughout the 1980s, the FDA permitted all amino
acids to be marketed illegally as dietary supplements.
Many of these products made illegal drug claims that
were also ignored by the agency.
What is perhaps most alarming, in my opinion, is the
fact that all of the amino acids on the market today in
supplement forms are illegal.
We fail to understand how FDA can allow the supple-
ment industry to flaunt Federal law, and this sends a
worse [sic] kind of signal, in my view, to the few un-
scrupulous marketers who are out there looking for an
opportunity to profit over health fraud. It jeopardizes
the health of all consumers and leaves honest compa-
nies at a competitive disadvantage.18
In 1990, Congress passed the Nutritional Labeling and
Education Act (NLEA).49 The Act, designed to expand and
modernize nutritional labeling on consumer products, gave the
FDA the power to regulate manufacturers' claims that products
prevent disease or confer health benefits. 5 The FDA chose to
authorize disease or health-related claims "only if the totality of
publicly available scientific evidence - including evidence from
well-designed studies conducted in a manner which is consistent
with generally recognized scientific procedures and principles -
supports the claim, and there is significant scientific agreement
among qualified experts that the claim is supported by such
evidence."''
148 Hearings, supra note 1, at 123 (closing statement of Representative
Patsy Mink, Chairwoman, House of Representatives, Human Resources and
Intergovernmental Relations Subcommittee of the Committee on Government
Operations).
.4. Nutritional Labeling and Education Act of 1990, Pub. L. No. 101-535,
104 Stat. 2353 (1990).
1 0 Charles J. Raubicheck & Leslye B. Davidson, Nutrition Labeling on
Products Must Comply with New Statute, DAILY REP. FOR EXEcUTIVES, June
16, 1993, at A114.
151 56 Fed. Reg. 60,537, 60,537 (1991). The FDA chose to establish the
same standard for health claims made on dietary supplements as those made
for claims for food. Id. at 60,539.
1994] 405
406 CORNELL JOURNAL OF LAW AND PUBLIC POLICY [Vol.3:383
In response, Congress passed the Dietary Supplement Act
of 1992 to prevent the FDA from implementing these
regulations. 5 2 The Act (1) placed a one-year moratorium on
FDA implementation of the NLEA with respect to dietary
supplements in forms other than conventional food, (2) called for
additional studies on FDA regulation of dietary supplements,
and (3) ordered the FDA to implement NLEA standards for
dietary supplements with a new rulemaking by 1993.11
In June 1993, the FDA proposed that product labels for
dietary supplements should contain the same nutritional infor-
mation as labels for processed foods.' Furthermore, the FDA
proposed that there should be "significant agreement among
qualified experts" concerning the veracity of such claims.' 5 In
reaction, three bills were introduced into Congress during the
session: The Dietary Supplement Consumer Protection Act of
1993,156 the Health Freedom Act of 1993,1'" and the Dietary
Supplement Health and Education Act of 1993.158 Each out-
lines a unique regulatory framework for dietary supplements.
Meanwhile, Canada acted quickly to regulate amino acid
marketing, 59 and, as a result, the EMS outbreak did not oc-
cur in Canada. 6 ' Only eleven cases of EMS were reported in
Canada, ten of which were traced back to L-tryptophan pur-
chased in the United States and later imported into Cana-
da.'6 ' L-tryptophan became available over-the-counter in Can-
ada in 1980.162 In 1985, Health and Welfare Canada, through
its Health Protection Branch, issued an Information Letter
152 The Dietary Supplement Act was appended to the Prescription Drug
User Fee Act of 1992. Pub. L. No. 102-571, 106 Stat. 441 (1992).
153 58 Fed. Reg. 33,690, 33,690 (1993).
154 id.
... FDA Calls for Dietary Supplements to Meet NLEA Labeling Require-
ments, DAILY REP. FOR EXECUTIvES, June 16, 1993, at A114.
156 H.R. 2923, 103d Cong., 1st Sess. (1993).
'5' H.R. 509, 103d Cong., 1st Sess. (1993).
15" H.R. 1709, 103d Cong., 1st Sess. (1992); S. 784, 103d Cong., 1st Sess.
(1993).
9 See Hearing, supra note 1, at 206 (Report of the Canadian Health
Protection Branch Expert Advisory Committee on Amino Acids).
'60 See id. at 205.
161 Id.
162 Id. at 195.
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which recategorized L-tryptophan as a new drug, stating that
"[p]roducts containing single amino acids or mixtures of amino
acids which have demonstrated pharmacological effects or for
which drug claims are made or implied are considered to be
drugs as defined in section 2 of the Food and Drugs Act."'1
63
Pursuant to this statement, L-tryptophan became regulated as
a prescription drug in. Canada.'" In 1987, the Canadian
Health Protection Branch established an Expert Advisory
Committee on amino acids, which delivered its final report in
1990.15 The Committee concluded that there is no substan-
tial reason to allow amino acids to be readily available to the
general public.
166
L-tryptophan was never taken off the market in Canada,
even at the height of the U.S. EMS epidemic. It is used today
as a drug in Canada. Meanwhile, in the United States, the
legal wrangling over L-tryptophan and other amino acids contin-
ues.
III. THE CONGRESSIONAL BATTLE OVER
DIETARY SUPPLEMENTS
By 1993, the battle over dietary supplements had become
heated."7 Two bills were introduced into Congress, two of
163 Id. at 211 (containing HPB Information Letter No. 685 (May 3, 1985)).
1'6 The Canadian Regulations were challenged in two cases. In Jamieson
& Co. v. Attorney General of Canada, 46 D.L.R.4th 582; 37 C.C.C.3d 193; 3
W.C.B.2d 164 (1987) (Canada), Jamieson instituted an action claiming that
amino acids were not new drugs as defined in the Food and Drugs Act. Id.
The court upheld the validity of the regulations and the status of amino acids
as new drugs. Id. In Regina v. Quest Vitamin Supply Ltd., Quest was
prosecuted for continuing to sell L-tryptophan without filing a new drug
submission. Regina v. Quest Vitamin Supply Ltd., 354 B.C.S.C. 3 (1991)
(Canada). The judge held for the plaintiff, stating that the court should
respect the general deterrence provided by these regulations and that the
public is entitled to rely on the integrity of health products and expect that
public health standards will be maintained and offenses punished. Id. at 10.
165 Hearing, supra note 1, at 85 (statement of Simon N. Young).
"
6 Id. at 196 (Report of the Canadian Health Protection Branch Expert
Advisory Committee on Amino Acids (1990)).
161 See Kathi Gannon, Vitamin Showdown: Who Should Control Dietary
Supplements?, DRUG ToPics, Jan. 24, 1994, at 38 (discussing the current state
of the debate over dietary supplements); Peace on Earth? ... Not! Supple-
ment Battle Rages, FOOD LABELLING NEwS, Dec. 23, 1993 (discussing tactics
employed by the dietary supplement industry to prevent regulations) [herein-
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which would allow dietary supplements to remain on the mar-
ket with little regulation.'68 The third bill proposed somewhat
stricter regulation.'69 Although none of these bills was voted
on during the session, each offered an insight into legislative
thought regarding amino acid dietary supplements in the
United States.
Governmental efforts to control dietary supplements and to
enact labeling requirements angered the supplement indus-
try."'° Through a grass-roots campaign largely centered on
massive lobbying' 7' and advertising efforts,'172 the industry
has incited consumers against the government's control efforts.
One source stated that members of Congress receive more mail
from their constituents regarding dietary supplements than any
other issue.'
3
Congress and the industry have focused on insuring that
dietary supplements remain readily available.'7 This Part
discusses several aspects of the argument between the FDA and
the industry, including the debate over health claims, the
scientific safety standards for dietary supplements, and the
procedures the industry must follow to avoid manufacturing
defects.
after Peace on Earth?].
" See Health Freedom Act of 1993, H.R. 509, 103d Cong., 1st Sess.;
Dietary Supplement Health and Education Act of 1993, H.R. 1709, 103d Cong.,
1st Sess.
.69 Dietary Supplement Consumer Protection Act, H.R. 2923, 103d Cong.,
1st Sess. (1993).
0 See Peace on Earth?, supra note 167.
171 Dante E.A. Ramos, Vitamin Makers Try a Dose of Lobbying, 30 NAT'L J.
1879, 1879 (1993). The Nutritional Health Alliance, formed in mid-1992, hired
lobbyist Anthony T. Podesta, a veteran lobbyist with close ties to the Clinton
Administration and several Democratic members of Congress, to wage the
battle. The alliance also sold a "health freedom kit" for $25, which included
Congress members' addresses, sample letters, and a toll-free number for
inspiration. Id.
1' Glenn Simpson, A Raid on Your Medicine Chest?, USA WEEKEND, Feb.
20, 1994, at 16. For example, the Health Freedom Task Force produced a
television commercial, starring actor Mel Gibson, in which an FDA SWAT
team overruns Gibson's home and confiscates his illegal vitamin C. Id.
173 id.
74 See Mike McKee, Odd Alliance Fights ADA Plan, RECORDER, July 29,
1993, at 1.
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A. ADVERTISING HEALTH CLAIMS
Since the passage of the Nutrition Labeling and Education
Act (NLEA),7 5 the dietary supplement industry and the FDA
have been at odds over the extent to which the FDA should
regulate product claims made by the industry."6 The NLEA
granted the FDA discretion to determine the standards applica-
ble to product claims for dietary supplements. 77 The FDA
repeatedly chose to apply the same standards for health-related
claims made regarding dietary supplements as those required
for health-related claims regarding food.
17
The supplement industry responded by making strongly
anti-regulatory statements, many of which inaccurately por-
trayed the FDA's intended regulations. 17 9  For example, one
industry statement claimed that the FDA planned to remove
well-established health food staples - such as vitamin C -
from the shelves of pharmacies and health food stores. 8 ' In
fact, the FDA made no such threat. 1'
175 21 U.S.C. § 343 (1988 & Supp. IV 1992).
171 See Richard L. Frank & Michael J. O'Flaherty, Government Regulation
of Self-Care, RECORDER, Oct. 13, 1993, at 10; FDA Calls for Dietary Supple-
ments to Meet NLEA Product Requirements, DAILY REP. FOR EXECUTIVES, June
16, 1993, at 114.
177 The Act provides that "a subparagraph (1)(B) claim made with respect
to a dietary supplement of vitamins, minerals, herbs, or other similar nutri-
tional substances shall not be subject to subparagraph (3) but shall be subject
to a procedure and standard, respecting the validity of such claim, established
by regulation of the Secretary." 21 U.S.C. § 343(r)(5)(D) (Supp. IV 1992).
17 See Part I.C. supra (concerning FDA's implementation of the Nutritional
Labeling and Education Act).
179 See Peace on Earth?, supra note 167.
10 See id.
181 Id.
The bogus threat that ordinary daily dietary supplements, such as
multi-vitamins, will be banned is a scare tactic by some in the
industry who hope it will earn them a blank check from the govern-
ment to make unproven health claims for mega-vitamins, amino
acid products and herbal extracts.
But the government must not write that check. Instead, it should
halt unproven health claims for offending products and protect
consumers by getting off the market those supplements that are
potentially dangerous.
Many ordinary vitamin and mineral supplements may prove useful
.... The usefulness of ordinary substances in ordinary doses is one
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The dietary supplement industry also accused the FDA of
an anti-supplement bias, claiming that "the dietary supplement
industry has been willing to cooperate with the FDA whenever
issues of public safety are concerned.. .. 82 and that the "FDA
has chosen to use extreme examples of products which reflect a
very small segment of the dietary supplement industry to make
its case against the whole industry."'18 3 However, recent in-
dustry advertising contradicts these statements of good
faith. 8 4 In 1992, an advertisement for a product containing
L-tryptophan appeared in a bodybuilding magazine. 8 5 The
product contained one thousand milligrams of L-tryptophan
(suggesting manufactured L-tryptophan). 8 6  The advertising
company did not list its name and address. 187 Another adver-
tisement for a product containing levodopa, a prescription drug,
did not list a recommended dosage or possible side effects.
188
Another product listed hydrangea as an ingredient, even though
the leaves and buds of the hydrangea, if consumed, can cause
cyanide poisoning.19 Overall, the researchers found that fifty-
nine percent of the advertised products contained no toxicologi-
cal information, that they made little mention of side effects or
contraindications, and that they rarely stated recommended
thing. Unsubstantiated claims for prevention, cure or treatment of
specific illnesses is quite another.
Id. (quoting Mark Silbergeld, director of the Washington Office of Consumer's
Union).
182 Opinions Collide on FDA's Supplement Advance Notice, FOOD LABELING
NEWS, Jan. 27, 1994 (quoting Nutrilite Products, Inc.).
183 Id.
18 See Philen et al., supra note 102, at 1009.
1 5Id. The advertisement ran even though L-tryptophan was recalled from





'"9 Id. at 1010.
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dosages.19 Blatantly self-serving and misleading advertising
and drug claims are not indicative of good faith.
Nevertheless, the dietary supplement industry and Con-
gress persist in attempts to circumscribe the FDA's power to
stop inappropriate health claims. The proposed Dietary Supple-
ment Health and Education Act of 1993 would prohibit the FDA
from stringently regulating dietary supplement health
claims.'9 ' The Act would also allow manufacturers to set forth
information about how the dietary supplement will "affect
physiological processes of the body or prevent or repair damage
caused by the diet or other environmental factors and does not
authorize the Secretary to establish a prior restraint on the use
of any labeling...."'9'
If the FDA does not have the power to regulate manufac-
turers' claims, the result will be exaggerations, half-truths, and
190 The researchers reached the following conclusions:
Although our report focuses on general health and bodybuilding
magazines, persons taking supplements for other reasons may be
... vulnerable to advertising claims .... In particular, persons
with chronic diseases such as arthritis, those with poorly under-
stood syndromes such as chronic fatigue syndrome or premenstrual
syndrome, or those with terminal diseases such as some cancers
may be particularly susceptible to the alleged health benefits of nu-
tritional supplements. These products may also be used by individ-
uals for symptoms such as insomnia, digestive discomforts, 'nerves'
or for the promotion of general well-being. The claims of beneficial
health effects made for many of these products are based only tenu-
ously, if at all, on information from peer-reviewed research. Prod-
ucts are promoted to the public as being 'natural' and 'organic' when
in fact most ingredients in these products are from manufactured or
chemically derived sources.
Id.
191 H.R. 1709, 103d Cong., 1st Sess. § 4 (1993).
192 Id. This information must be truthful and not misleading. Although
this appears to stop the supplement industry from making outrageous claims,
the scientific standards set to define when a claim is truthful and not mislead-
ing are low enough that claims could be made with ease. The bill merely
provides:
A dietary supplement containing a nutrient for which the FDA has
approved a given health claim, may make that claim on its label
unless the Secretary determines, based on the totality of publicly
available scientific evidence, that consumption of the nutrient would
not tend to reduce the risk of disease or other health-related condi-
tions in a manner similar to the consumption of such nutrient in
conventional foods ....
19941
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marginally substantiated facts. 9 3 Individuals relying on mar-
ginal health claims are in danger of foregoing assistance at the
onset of an illness, thereby losing valuable recovery time. If a
simple, inexpensive bottle of amino acid X can cure a symptom,
why go to a doctor? However, if amino acid X relieves only a
symptom stemming from a serious condition, health care profes-
sionals will become involved later, perhaps at a more complex
stage of the illness.
The strict regulation of manufacturers' health claims made
by dietary supplement manufacturers is an admirable goal, but
does not reach the heart of the problem. Certain amino acids
are unsafe or useless for human consumption, even when not
contaminated.' Quite simply, amino acids can be danger-
ous. 9  Therefore, attempts to regulate or deregulate health
claims do not address the inherent health risks of amino acids.
The pertinent question is whether amino acids should be readily
available at all.
B. THE SAFETY OF DIETARY SUPPLEMENTS
1. Scientific Standards of Safety
Another front in the battle over dietary supplement regula-
tion is the strictness of the scientific standard manufacturers
must meet before (1) they may make health claims and (2) have
products deemed safe for sale to consumers. As of this writing,
only one of the proposed bills gives the FDA adequate authority
to protect the public. 9 '
One proposal allows the manufacturer to determine that its
product is safe.'97 If enacted, this proposal would replace the
193 See supra notes 94-102, 184-190 and accompanying text.
194 See supra notes 46-53, 86-92 and accompanying text.
195 See id. and notes 1-10 and accompanying text.
196 H.R. 2923, 103d Cong., 1st Sess. § 6 (1993).
197 It specifies:
A food shall be deemed to be adulterated [ilf it is a dietary supple-
ment and... (2) it contains a dietary ingredient that has not been
adequately substantiated for safety by the person identified under
section 403 (e)(1) or by the raw material manufacturer through-
(A) evidence of a history of safe use (as part of any prior intended
use) and the absence of substantial information that brings the
safety of the ingredient into question; or (B) by well-designed
scientific studies conducted in a manner that is consistent with
REGULATION OF AMINO AcIDs
FDA's disinterested determination with that of financially
interested parties, thereby reducing the consumer's assurance
that a dietary supplement has been adequately proven safe. If
all that is to be required of a manufacturer is proof of a history
of safe use, well-designed scientific studies, or other appropriate
means, the manufacturer has excessive room to maneuver.
Manufacturers may rely on studies that are neither published,
generally accepted within the scientific community, nor defini-
tive. Furthermore, scientists supported by a manufacturer
could easily develop a bias toward their sponsor. Using the
L-tryptophan scenario as a guide, consider the following:
studies show that L-tryptophan may have effective pharmaco-
logical uses if its potential is correctly developed. 9 However,
other studies show that L-tryptophan could be dangerous if not
used with extreme care. 9 9 If manufacturers retained control
over the determination of safety, the studies which show L-tryp-
tophan to have potential health benefits would be sufficient to
allow it to remain on the market. Unless the FDA could meet
the stringent burden of proving that the studies showing poten-
tial problems of the supplement presented "a substantial and
unreasonable risk of illness or injury,, 20 the studies revealing
potential health problems connected with the product would be
ineffective evidence to prevent a manufacturer from marketing
the product. The disinterested regulator should not be bound by
the safety determinations of the financially interested manufac-
turer.
An alternative is to require general recognition of the
product's safety.20' This more stringent requirement would
generally recognized scientific procedures or principles; or (C) by
other appropriate means.
Id. § 3(f).
19' Hearings, supra note 1, at 70 (statement of Richard J. Wurtman, M.D.,
Professor of Neuroscience and Director, Clinical Research Center, Massachu-
setts Institute of Technology).
199 See Id. at 64 (statement of Esther M. Sternberg, M.D., Chief, Unit on
Neuroendocrine Immunology and Behavior, Clinical Neuroendocrinology
Branch, National Institute of Mental Health, Alcohol, Drug Abuse, and Mental
Health Administration).
20o H.R. 1709, 103d Cong., 1st Sess. § 3(a)(F)(1) (1993).
201 The proposed Dietary Supplement Consumer Protection Act states that
a dietary supplement shall be deemed unsafe unless "such ingredient is
generally recognized, among experts qualified by adequate training and
experience to evaluate its safety, as having been adequately shown through
19941 413
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give the FDA the power to keep a questionable dietary supple-
ment off the market. By requiring general recognition of the
safety of dietary supplements, the FDA could withhold approval
of a supplement until the scientific community has concluded
that such a supplement is safe.20 2 Thus, this requirement
would assure that no supplement manufacturer could, relying
solely on a single study or a manufacturer-financed study, push
an unsafe product onto the American market.
Not surprisingly, the dietary supplement industry is strong-
ly opposed to the general recognition of safety and significant
scientific agreement standards as defined by the FDA.2"3 One
industry organization, the Council for Responsible Nutrition,
alleges that the FDA interprets the word "agreement" to mean
"consensus" in the context of this proposal." 4  The industry
argues that under this regulatory framework it would be nearly
impossible for dietary supplements to have easy access to the
market. °5 However, if the issue is the safety of dietary sup-
plements, it is best to err on the side of caution. The alter-
native to cautionary regulations requiring product testing is to
allow manufacturers to market potentially unsafe dietary
supplements and place consumers at risk. As the plight of EMS
victims demonstrates, the human suffering caused by reliance
on unsafe products far outweighs the difficulty of meeting the
requirement of general recognition of safety.
206
scientific procedures to be safe under the conditions of its intended use ......
H.R. 2923, 103d Cong., 1st Sess. § 6(a)(2) (1993).
202 
Id.
203 With Supplement Showdown Approaching, CRN Calls for Action, FOOD
LABELING NEwS, Jan. 20, 1994.
204 Id.
205 See Vitamin Showdown, supra note 167 (quoting Gerald Kesler, CEO of
Nature's Plus, a dietary supplement manufacturer).
206 The American Medical Association supports the FDA in its attempts to
regulate dietary supplements: "We commend the FDA's efforts to ensure the
safety of dietary supplements by increasing the responsibility of supplement
manufacturers .... The full potential of the relationship between nutrition
and health can only be realized after dietary supplements meet the standards
that consumers expect and deserve of any product for human consumption."
Opinions Collide, supra note 182.
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2. Regulating the Manufacturing Process
Two of the current proposals seek to ensure the safety of
dietary supplements by requiring nianufacturers to be candid
about their manufacturing processes. 7 One proposal deems
a dietary supplement to be adulterated - and thus unmarket-
able - if the manufacturer does not notify the Secretary of the
FDA of significant changes in the manufacturing process.
However, as this requirement only applies if the changes in the
manufacturing process are substantial and produce safety
risks,209 the proposal does not ensure effective regulation of
the manufacture of dietary supplements. This vague and open-
ended loophole results in two major concerns.
First, "significant changes" in the manufacturing process
remain undefined in the proposal.2 10 Although the Secretary
is given the power to promulgate regulations requiring notifica-
tion of manufacturer changes, these changes must be "substan-
tial.' 21  The phrase "substantial changes" is highly subjective.
Although the Secretary may interpret its meaning, the interpre-
tation would have to be very complex. Is it a substantial change
when a manufacturer uses a stronger strain of a bacteria which
207 S. 784, 103d Cong., 1st Sess. (1993); H.R. 2923, 103d Cong. 1st Sess.
(1993).
211 Under this proposal, a dietary supplement would be deemed adulterat-
ed:
(G)(1) If it is a dietary supplement and the Secretary was not
notified, in accordance with regulations issued under subparagraph
(2), about a significant change in the manufacturing practice which
produced the supplement or of potential problems of safety or
contamination affecting such practice.
(2) The Secretary shall promulgate regulations within 18 months of
the date of the enactment of this subparagraph to require notifica-
tion to the Secretary by manufacturers of raw materials utilized in
dietary supplements of significant changes in manufacturing
practices of such materials or any potential problems of safety or
contamination arising from any such changes to ensure the safety
of such materials.
H.R. 1709, 103d Cong., 1st Sess. § 3 (1993).
20 "Subparagraphs (1) and (2) apply only to manufacturing changes that
are substantial and have been shown to present adverse safety consequences.
These sections do not apply to routing changes in the formulating and
manufacturing of dietary supplements by dietary supplement manufacturers
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has been used all along in a weaker form? Is it a substantial
change to bypass a reverse-osmosis filtration process? Is it a
substantial change to reduce the amount of activated carbon in
a batch of the product? To one process any change may be
substantial, to another some changes may be insubstantial.
Given the current state of affairs between the FDA, Con-
gress, and the dietary supplement industry, the FDA may do
one of two things, neither of which would effect a perfect solu-
tion. The Secretary could enact, through rulemaking, a very
strict standard for "substantial changes." This rulemaking
would cause a further deterioration in the relationship between
the FDA and the supplement industry and circumvent the will
of Congress, although it would provide a high level of protection
to the public. Alternatively, the FDA could back away from
regulation in this area, as they did in the 1970s.2 12 Although
the dietary supplement industry would thrive if unregulated,
the American public should not be placed at such a risk.
The second source of concern regarding this proposal is that
it does not require notification by the manufacturer unless the
changes are not only substantial, but also "have been shown to
present adverse safety consequences." 1 Even if the Secretary
does define "adverse safety consequences" through rulemaking,
the use of the phrase "have been shown" implies that there
must have been past problems associated with the process. The
FDA will then not have the ability to reject new manufacturing
procedures which have not yet been shown to have adverse
safety consequences. This requirement of adverse safety conse-
quences would be hopelessly after-the-fact. Once a manufactur-
ing change has produced safety problems, it is too late to re-
quire a notification of changes. The damage has already been
done, and an investigation of the cause of the problem will
ensue with or without a notice of changed manufacturing
practices to the Secretary. All prospective manufacturing
changes should be reported to the Secretary, thereby providing
him or her with an opportunity to spot potential safety prob-
lems.
The second proposal considers a dietary supplement adul-
terated if it has not been produced in accord with good manufac-
turing processes and quality control procedures, as determined
212 See supra notes 70-80 and accompanying text.
213 H.R. 1709, 103d Cong., 1st Sess. § 3(g)(3) (1993).
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by the Secretary.214 This proposal does not contain a provi-
sion requiring the manufacturer to notify the FDA in case of
manufacturing changes. Although the proposal does require
good manufacturing processes, its failure to require notification
upon change of the processes - as discussed above - could be
fatal to consumers and should be fatal to the proposal. The
proposal contains a notification provision, but this provision
applies only when someone in the chain of distribution knows
that a supplement may be adulterated.215 This is too after-
the-fact to provide adequate protection to consumers. Once it is
known that a product is adulterated, the adulteration has
already occurred, and the change, maybe even the damage, is
done.21 6
No regulation of the manufacturing process is effective
unless it provides that the FDA receive notice of proposed
changes in the manufacturing process. Along with that notice,
the FDA should be given the power to disallow the change217
or require particular testing. At a bare minimum, the FDA
should receive notice of proposed manufacturing changes so that
it would have a record on file in case a safety problem does
arise and product tracing becomes necessary.
214 It states:
[A] dietary supplement shall be deemed to be adulterated (g)(1) If
... it does not meet the quality factor requirements prescribed by
the Secretary under this paragraph. The Secretary shall, by regula-
tion, establish requirements for quality factors for dietary supple-
ments as appropriate.
(h)(1) If... the processing of such dietary supplement is not in
compliance with the good manufacturing practices and the quality
control procedures established by the Secretary under subparagraph
(2).
(2) The Secretary shall, by regulation, establish good manufacturing
practices for dietary supplements, including quality control proce-
dures that the Secretary determines are necessary to assure that a
dietary supplement-
(A) provides the vitamin, mineral, or herb or other nutritional
substance it claims to provide in its label or labeling, and
(B) is manufactured in a manner designed to prevent adulteration.
H.R. 2923, 103d Cong., 1st Sess. § 4 (1993).
215 Id. § 6.
216 For a definition of what shall be considered adulterated, see 21 U.S.C.
§ 342 (1988 & Supp. IV 1992).
217 Such disallowance could be predicated upon previous safety problems or
experimental results that indicate that the change may be unsafe.
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IV. THE CANADIAN REGULATORY FRAMEWORK
As a consequence of the Canadian Constitution's division of
power between the federal government and the country's region-
al provinces,218 the Canadian Food and Drugs Act 19 was en-
acted as a criminal statute.22 ° The Constitution creates feder-
al jurisdiction over trade, commerce, and criminal law,22' leav-
ing jurisdiction over things such as property and civil rights -
as well as local or private matters - to the provinces. 222
Because the authority to regulate pharmaceuticals was not
explicitly included in this division of power, Canada's federal
government gained regulatory control over food and drugs in
Canada through the use of criminal laws.22
The Health Protection Branch ("HPB") of Health and
Welfare Canada is akin to the FDA in the United States. This
agency oversees the availability of Canada's food, drugs, cosme-
tics, and medical devices, and is empowered to control environ-
mental hazards.224 The HPB decides whether or not to bring
charges against food or drug manufacturers that fail to comply
with Canadian law.
HPB compliance procedures ensure that there is very little
food and drug litigation in Canada. 5 In order to avoid litiga-
tion when there is a compliance question, the HPB consults
with manufacturers, attempts to persuade them to comply with
218 CAN. CONST. art. VI (British North America Act, 1867).
219 Food and Drugs Act, R.S.C., ch. F-27 (1985) (Canada).
220 Robert E. Curran, Canadian Regulation of Food, Drugs, Cosmetics, and
Devices - An Overview, 30 FoOD DRUG COSM. L.J. 644, 644 (1975).
221 W. Wassenaar, Canada: Evolution of Drug Regulation within the
Health Protection Branch, 35 FoOD DRUG COSM. L.J. 451, 453 (1980).
222 Id.
223 Id.
224 A.B. Morrison, The Canadian Approach to Food and Drug Regulations,
30 FOOD DRUG CosM. L.J. 632, 632 (1975). Morrison states that the HPB's
responsibilities include most of those handled in the United States by the
FDA, and some of those handled by the Communicable Disease Center and the
Environmental Protection Agency. Id. at 632-33.
22 Curran, supra note 220, at 645. "We do not have a Food and Drug
Section of the Canadian Bar Association, nor, for that matter, do we have a
food and drug bar. There are relatively few lawyers in Canada who specialize
in the subject .. " Id. at 644.
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the law,226 and, only if necessary, files suit against a noncom-
plying manufacturer.
Some commentators have criticized the HPB's use of selec-
tive enforcement policy.227 First, the procedure creates prob-
lems of selective justice.22 Large corporations with abundant
resources can defend against the allegations of the HPB or cure
the fault found in their methods. However, small companies,
when faced with the same allegations, are more likely to pay a
fine or go out of business than mount a defense or institute the
necessary technical renovation.229 Second, a violator suffers a
public relations disaster if it is listed in the HPB-authored
Protection, a bulletin that lists all convictions under the Food
and Drugs Act." Finally, there is a problem of insufficient
notice and public comment on proposed regulation. Changes in
Canadian drug regulations may be spurred by elected officials,
the HPB, trade associations, or consumers.2"' Once a regula-
tion is proposed, the government is under no obligation to allow
those affected by the regulation a period in which to make
comment.23 2 The HPB merely provides information about how
the new regulations will impact manufacturers, prints adminis-
trative interpretations of the new regulations, and invites
comments on the changes21
3
The Food and Drugs Act itself is divided into four parts.
Part I describes what is proscribed with regard to food, drugs,
226 Id. at 645.
' See, e.g., Wassenaar, supra note 221, at 455-59.
22 8 Id. at 456.
229 Id.
" Id.; James A. Robb, Comments and Views from the Perspective of a
Canadian Food Lawyer 30 FOOD DRUG COSM. L.J. 659, 661-62 (1975).
[W]hen a matter has reached the stage of prosecution, it is often
difficult for a lawyer to give advice other than to plead guilty. The
Act is, in fact, a prosecutor's act. Charges are in general terms, and
distinct advantages are given departmental expertise in administra-
tion and enforcement .... Defense becomes difficult and, aside
from the fine, the public relations consequences of this type of
charge are difficult, if not impossible, to overcome. A guilty plea is
often the better part of valor.
Id.
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cosmetics, and devices.3 4 Part I of the Act prohibits the ad-
vertising of any product as a cure for a certain group of dis-
orders,2 35 the sale of adulterated drugs or drugs manufactured
under unsanitary conditions,23 6 and deceptive or misleading
advertising of food,237 drugs,"' and devices.239 Part II con-
tains the Act's administrative procedures and enforcement
provisions.240 The Act arms drug inspectors with broad en-
forcement authority.24' Parts III and IV of the Act cover con-
trolled prescription drugs, "restricted" drugs, and drug traffick-
ing.
2 4 2
The Canadian Food and Drugs Act defines a drug as any
substance manufactured, sold, or represented for use in (a) diag-
nosis, treatment, mitigation, or prevention of disease, disorder,
abnormal physical state, or associated symptoms, or (b) the
restoring, correcting, or modifying of organic functions, or (c) the
disinfection of premises in which food is prepared or manufac-
tured.243 From 1980 through 1985, amino acids - including
L-tryptophan - were sold over-the-counter in Canada.2" In
1985, the HPB issued an information letter classifying as drugs
products containing amino acids with demonstrated pharmaco-
4 Food and Drugs Act, R.S.C., Ch. F-27, § 3(1) (1985) (Canada).
235 Id.
26 Id. § 8(a), (b).
237 Id. § 6.
m Id. § 9(1).
29 Id. § 20(1).
240 See id. § 23.
241 Wassenaar, supra note 221, at 453.
Indeed the powers of a drug inspector are much greater than [those]
of a police officer. The police officer must at least obtain a search
warrant before entering any premises. An inspector does not need
any warrant and may enter any building and make any seizure on
'reasonable' grounds that the premises or object of seizure is subject
to the Act or regulations.
Id.
242 Parts III and IV of the Food and Drugs Act are beyond the scope of this
Note.
243 Food and Drugs Act, R.S.C., ch. F-27, § 2 (1985) (Can.); see also Hear-
ing, supra note 1, at 196 (Memorandum from Catherine Wingfield, Legal
Specialist, American-British Law Division, Library of Congress).
2 Hearing, supra note 1, at 85 (statement of Simon N. Young, Ph.D.,
Professor, Department of Psychiatry and Professor, School of Dietetics &
Human Nutrition, McGill University).
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logical effects." 5 Further, products containing single amino
acids or mixtures of amino acids "which have demonstrated
pharmacological effects" or for which such claims were made
were regarded by the HPB as "new drugs. '"2 4' Regulations
promulgated under the Canadian Food and Drugs Act define a
new drug as: (a) a single substance which has not been sold as
a drug in Canada for a sufficient time to establish that the
substance is safe and effective; (b) a combination substance drug
which has not been sold as a drug in that proportion in Canada
for sufficient time to establish that the combination is safe and
effective; or (c) a drug which the manufacturer states to have a
specific use, and which has not been sold for a sufficient time in
Canada to establish that the use is safe and effective.247
In order to distribute a new drug in Canada, a manufactur-
er must file a "New Drug Submission," obtain a "Notice of
Compliance," and submit proposed packaging for the new
drug.' If the HPB does not approve the New Drug Applica-
tion, the manufacturer may resubmit the application to the
Minister of National Health and Welfare. 9
In 1986, the Bureau of Human Prescription Drugs permit-
ted the pharmaceutical company ICN Canada to market L-tryp-
tophan as a prescription drug for the treatment of affective
disorders.25 ' L-tryptophan continues to be available in Cana-
245 Health and Welfare Canada, Health Protection Branch, Information
Letter No. 685 (May 3, 1985), reprinted in Hearing, supra note 1, at 209.
24 Id. at 212; Food & Drugs Act Regulations, C.R.C., ch. 870, § C.08.001(a)-
(c) (1978) (Can.).
247 Food & Drugs Act Regulations, C.R.C., ch. 870, § C.08.001(a)-(c) (1978)
(Can.).
248 Id. § C.08.002(1)(a)-(d).
249 Id. § C.08.004. The Canadian process of New Drug Applications is
substantially similar to the U.S. process, even to the point that Health and
Welfare Canada accepts a copy of the New Drug Application submitted to the
FDA as a Canadian application. However, Canada and America do not
reciprocate with regard to drug approval. Even after one country approves the
application, the other conducts a separate review. Curran, supra note 220, at
648.
25 Hearing, supra note 1, at 85 (statement of Simon N. Young). Affective
disorders are "[a] group of disorders characterized by a disturbance of mood
accompanied by a full or partial manic or depressive syndrome that is not
caused by any other physical or mental disorder." TABER'S, supra note 3, at
48.
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da, under the name "Tryptan. " 251 No cases of EMS have been
linked to patients taking Tryptan.252
In 1987, the HPB organized an Expert Advisory Committee
to study the use of amino acids in pharmaceuticals.5 3 The
Committee submitted a report to Health and Welfare Canada in
December 1989, during the EMS outbreak.2 4 Among the con-
clusions of the Expert Advisory Committee was the determi-
nation that:
[t]here would appear to be no convincing rationale for
having amino acids generally available to the public. If
amino acids exert the pharmacological effects claimed,
they are unsafe if not taken under medical supervision
for a specific benefit; if they don't exert these effects,
then there is no reason for marketing them. Further-
more, all of these amino acids were considered to have
the potential for producing certain toxic effects in sus-
ceptible individuals or if consumed in large amounts for
an extended duration.255
By May, 1990, only ten cases of EMS had been reported in
Canada." 6 Eight of those who became ill had purchased sin-
gle-ingredient L-tryptophan products in the United States; the
ninth had ingested an L-tryptophan-containing compound
formulated at a Canadian pharmacy; and the tenth had ingested
L-tryptophan distributed in the United States and illegally sold
in Canada.257
Classifying amino acids as drugs has worked well in Cana-
da. Although legislation pending in the U.S. Congress eschews
classification of all dietary supplements as drugs, regulating the
"1 Hearing, supra note 1, at 85.
25 2 Id. at 86.
" Id. at 81 (statement of Simon N. Young, Ph.D., Professor, Department
of Psychiatry and Professor, School of Dietetics & Human Nutrition, McGill
University).
( Id. at 204 (referring to HEALTH AND WELFARE CANADA, REPORT OF THE
EXPERT ADVISORY COMMITTEE ON AMINO AcIDS (1990)).
255 Id.
"
6 Eosinophilia Myalgia Syndrome - Canada, 39 MORBIDITY & MORTALI-
TY WKLY. REP. 326, 326 (1990).
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subcategory of amino acids as drugs would offer viable protec-
tion for the American people." 8
V. WHAT SHOULD BE DONE?
A. REGULATE AMINO ACIDS AS DRUGS
At the House Subcommittee Hearing on the FDA's Regula-
tion of L-tryptophan, Dr. Richard J. Wurtman, Professor of
Neuroscience and Director of the Clinical Research Center at
the Massachusetts Institute of Technology, enumerated several
reasons why amino acids such as L-tryptophan should be regu-
lated as drugs. First, it is not natural for a human to ingest
any amino acid individually. Tryptophan in pill form is not a
nutritional supplement and cannot be used by the body." 9
Second, since administering tryptophan in pill form changes the
chemistry of the brain, 6 ' it is a drug. Third, drugs have to be
proven safe and efficacious and must contain package inserts
listing contraindications and side effects,26' both of which
greatly benefit potential consumers of L-tryptophan. In addi-
tion, when L-tryptophan is marketed as a nutritional supple-
ment, pharmaceutical companies have less incentive to deter-
mine whether it could be a useful drug. 2 Finally, more
' In the U.S., a New Drug Application must include substantial evidence
of safety and efficacy of the drug, based on animal and human research. In
addition, the applicant must include literature on the use of the drug in the
U.S. and foreign countries. Jeffrey N. Gibbs & Bruce F. Mackler, Food and
Drug Administration Regulation and Products Liability: Strong Sword, Weak
Shield, 22 ToRT & INS. L.J. 194, 204 (1987).
29 Hearings, supra note 1, at 71 (statement of Richard J. Wurtman, M.D.,
Professor of Neuroscience and Director, Clinical Research Center, Massachu-
setts Institute of Technology).
260Id.
261 Id. at 71-72. For example, patients taking cardiovascular or psychiatric
drugs should not take L-tryptophan concurrently. Furthermore, one side
effect of L-tryptophan is tiredness; therefore, one should never drink alcohol
or drive after its ingestion. Id.
2 2 Id. at 72. When Dr. Wurtman first researched tryptophan and discov-
ered it had an effect on the serotonin levels of the brain, he hoped that a
pharmaceutical company might do more research and invest the money to do
safety and efficacy studies before bringing it to the market as a drug. As long
as it remains a dietary supplement, he states, no pharmaceutical manu-
facturer will take the time or effort to do these studies because a consumer
can get the substance more quickly and without a prescription through health
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accidents occur when amino acids are sold over the counter. It
is not just impurities that make amino acids unsafe; these
compounds can cause dangerous reactions when sensitive people
ingest them.263 A Canadian researcher, Dr. Simon Young of
McGill University's School of Dietetics & Human Nutrition,
agreed with Dr. Wurtman on similar grounds, stating that
although L-tryptophan in its unadulterated form is one of the
safer drugs on the market, it is not without its risks.2"
Questions remain as to whether the contaminated L-trypto-
phan would have entered the American market even if it were
regulated as a drug. Dr. Wurtman thinks not. If L-tryptophan
had been classified as a drug, the FDA would have been able to
oversee changes in the manufacturing process and ensure that
impurities were not introduced.265
Even if amino acids were regulated as drugs, the govern-
ment would not be able to catch every problem associated with
their ingestion. Some people would suffer allergic reactions, as
they do to drugs currently on the market. It is even conceivable
that contaminants would slip by since they are in such small
amounts.266 However, the federal government, including the
FDA, is against regulating particular amino acids as drugs.
After the L-tryptophan-related EMS outbreak, the FDA
received a study about amino acids by the Life Sciences Re-
search Office of the Federation of American Societies of Experi-
mental Biology (LSRO), and commissioned a Dietary Supple-
ment Task Force to study the problems related to amino acid
dietary supplements .1 7  Both studies support regulation of
amino acid dietary supplements as drugs. The LSRO listed
concerns about the continued unregulated use of amino acids.
food stores and catalogs. Id. at 70.
2
" Id. at 72. For example, tyrosine may be hazardous when taken in
combination with anti-depressants. Phenylalanine can be deadly when taken
by those persons who are unaware that their livers cannot adequately
metabolize it. Id. at 72-73.
2
" Id. at 81 (statement of Simon N. Young, Ph.D., Professor, Department
of Psychiatry and Professor, School of Dietetics and Human Nutrition, McGill
University).
25 Changes in the drug manufacturing process require FDA approval. Id.
at 92 (statement of Richard J. Wurtman, M.D., Professor of Neuroscience and
Director, Clinical Research Center, Massachusetts Institute of Technology).
266 The Show Denko L-tryptophan implicated in EMS was 99.6 percent
pure. Belongia et al., supra note 127, at 363.
267 Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,691 (1993).
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First, the LSRO could not identify a safe level of intake for
amino acids. Second, the LSRO identified certain segments
of the healthy population that had a higher risk of experiencing
negative effects due to amino acid consumption. 9  Third, it
stated that D-amino acids have no known nutritional function in
humans and thus should not be used.27 ' Fourth, the LSRO
recommended that dietary supplements' labels list the chemical
composition, isomeric identity, shelf life, dose, and contrain-
dications.2 1 Finally, the LSRO concluded "that the safety of
unrestricted use of amino acids in dietary supplements cannot
be assumed. 2
72
The Dietary Supplement Task Force recommended that
dietary supplements containing amino acids be regulated as
drugs.7 From studies of amino acid supplements, the Task
Force concluded that the "primary intended use of these prod-
ucts is for therapeutic rather than nutritional purposes. 27 4
As such, the amino acids should be regulated as drugs. By
regulating amino acids as drugs, the government would create
a hurdle for manufacturers to clear before placing their products
on the market. New drugs would have to meet two conditions
before clearance: (1) safety, and (2) efficacy for use under the
conditions recommended on their labelsY.2 5  Therefore, any
amino acid manufacturer attempting to get its product onto the
market must prove not only that the product is safe, but also
that it effectively treats the condition they claim it treats. The
latter requirement would force more studies to determine the
beneficial uses of amino acids and might uncover positive proof





272 Id. at 33,692.
273 Id. at 33,697.
274 id.
275 21 U.S.C. § 321(p) (1988) provides that a "new drug" is
(1) Any drug... the composition of which is such that such drug is
not generally recognized, among experts qualified by scientific
training and experience to evaluate the safety and effectiveness of
drugs, as safe and effective for use under the conditions prescribed,
recommended, or suggested in the labelling thereof....
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In August 1990, a memo from the Director of the Center for
Food Safety and Applied Nutrition, a branch of the FDA, dis-
cussed and quickly rejected the possibility of regulating amino
acids as drugs.27 The Center for Drug Evaluation and Re-
search, another FDA branch,277 determined that the FDA
would have to declare that amino acids have no nutritional
value in order to succeed in a case challenging the definition of
amino acids as drugs." 8 The agency would not contend that
amino acid supplements had no nutritional value, although
experts such as Dr. Wurtman and Dr. Young both stated that
any use of a single amino acid supplement would be pharmaco-
logical and not nutritional."9
Canada has had good results regulating amino acids as
prescription drugs. None of the proposed U.S. Acts would
regulate amino acids as stringently. To protect people from
dietary supplement-related diseases in the future, the U.S.
government should assure the safety and efficacy of every
supplement on the market by regulating amino acids as drugs.
Current Congressional actions, however, combined with the
U.S.'s heavy emphasis on consumer freedom, indicate that regu-
lating amino acids as drugs may not be politically or socially
viable, even though it may be the best way to insure public
safety.
276 Hearing, supra note 1, at 222-31 (draft memorandum from the Director
of the Center for Food Safety and Applied Nutrition to the FDA Commissioner
(Aug. 30, 1990)).
277 Id. at 227. The Center for Drug Evaluation and Research is another
component branch of the FDA which researches both investigational new
drugs and new drug applications involving bioengineered products. Linda
Maher, The Environment and the Domestic Regulatory Framework for Biotech-
nology, 8 J. ENvrL. L. & LrIG. 133, 144 (1993).
278 Hearing, supra note 1, at 227. The Center only grants drug status to
"(1) those products being clinically studied following submission of an [investi-
gational new drugs] or [new drug applications], and (2) those products labeled
with obvious statements regarding mitigation of disease or direct claims of an
effect on the structure or function of the human body." Id. at 226.
2 19 Id. at 71 (statement of Richard J. Wurtman, M.D., Professor of Neuro-
science and Director, Clinical Research Center, Massachusetts Institute of
Technology); id. at 81 (statement of Simon N. Young, Ph.D., Professor,
Department of Psychiatry and Professor, School of Dietetics & Human
Nutrition, McGill University).
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B. REGULATE AMINO ACIDS AS NON-DRUG ITEMS, BUT INCLUDE
STRICT STANDARDS FOR PUBLICLY MARKETED SUPPLEMENTS
Since the U.S. government does not appear ready to regu-
late amino acid dietary supplements as drugs, Congress should
enact laws that clearly indicate the status of dietary supple-
ments on the U.S. market. Although the supplements would
remain easily obtainable, the inclusion of particular require-
ments in the regulations would reduce the chances for wide-
spread future outbreaks of dietary supplement-related illnesses.
(1) Include amino acids explicitly in the regulations
Amino acids are not mentioned by name in most current
dietary supplement regulations, and that has caused problems.
Supplement manufacturers should no longer be able to argue
that, since amino acids are not mentioned by name, they do not
come within the scope of the regulations. Including amino acids
in the regulation would prevent further litigation and grant the
FDA clear-cut authority over the sale of amino acid dietary
supplements in the United States.
(.2) Explain where amino acids fit under the Food, Drug,
and Cosmetic Act so there will not be bureaucratic
or legal tussles over whether amino acids are food
additives or drugs
A statement that amino acids are either drugs or food
additives would clarify the standing of amino acids. In this
way, someone taking amino acid X for bronchitis and another
taking it for an X deficiency would no longer be using the same
substance classified in two different ways - the former classi-
fied as a drug, but the latter as a dietary supplement.
Amino acids also could be differentiated on a case-by-case
basis, regulating them as drugs for use in disease prevention or
control28 or for their ability to change bodily structure or
function;28' and also regulating them as either food additives
or nutritional supplements, assuming non-pharmacological, non-
harmful nutritive uses of certain amino acids are discovered.
Case-by-case decisions regarding in which category each amino
2'0 21 U.S.C. § 321(g)(1)(B) (1988 & Supp. IV 1992).
28 Id. § 321(g)(1)(C).
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acid supplement belongs would take time and use FDA resourc-
es; however, such decisions could be used to document the fact
that most amino acids are used for pharmacological, not nutri-
tive, uses. Proof that amino acids are used for predominantly
pharmacological purposes would bolster the currently unpopular
idea that amino acids are potentially dangerous and should be
regulated as drugs.
(3) Require substantial scientific agreement, based on
research done by independent parties, that an amino
acid is safe before it is placed on the market
One study, conducted by the manufacturer or a manufac-
turer-supported researcher, should never be sufficient to en-
dorse a supplement as safe. A supplement should be considered
safe and effective only after multiple research trials produce
positive results and relatively few negative outcomes. Such a
standard could have prevented the L-tryptophan EMS outbreak.
(4) Arrange a system providing for strict FDA supervision
of the manufacturing process
Establishing quality controls and purity standards would
minimize contamination of amino acid supplements. This alone,
however, will not prevent all supplement-related illnesses:
Some contaminants exist in small enough quantities to be
acceptable under most quantity control standards, but are
powerful enough to create illness.282 Manufacturers should be
required to obtain FDA approval of their manufacturing proce-
dures by filing a report with the agency. The FDA can reject
supplements if it finds that the manufacturing process used
creates an unreasonable risk of contamination. The FDA will
also have reports of the manufacturing processes on file if any
illnesses related to the supplement do occur.
(5) Require manufacturers to report any changes in their
manufacturing process
The FDA should require manufacturers to file notice of any
change in the manufacturing of their product, and a detailed
2 The Showa Denko L-tryptophan implicated in EMS was 99.6 pure.
Belongia et al., supra note 127, at 363.
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description of (1) the changes made, (2) the expected results of
the change, and (3) any potential, unintended effects of the
change which were noticed in the corporation's testing of its new
procedure. Such notice would highlight potential problems
before they occur and alert the FDA to reject the intended
changes in production methods to the extent that it deems them
unsafe or inconsistent with good manufacturing procedures. For
example, if the FDA had knowledge of the new methods Showa
Denko was using to manufacture L-tryptophan, it could have
required Showa Denko to maintain a higher amount of carbon
in the filtration process and prohibited the bypassing of the
membrane filter before allowing shipment of the drug into the
United States. This would probably have prevented the EMS
outbreak. At the very least, the FDA would have a record of the
change in the manufacturing process. If an outbreak of a
supplement-related disease occurs, having information about
changes in manufacturing process would allow the FDA to act
more quickly to minimize the damage."'
(6) Require inclusion of literature in the packaging
stating contraindications and side effects
related to the amino acids
All drugs come with warnings to those who should avoid the
drug, as well as information about the drug's potential side ef-
fects.' If such literature were required to accompany the
products containing amino acids, consumers would be able to
exercise informed consent before ingesting them rather than
relying solely on advertising claims indicating their good effects.
Manufacturers may truthfully advertise that amino acid X
' The FDA did not have the opportunity to inspect the L-tryptophan
manufacturing plant until May 1990, almost a year after the EMS epidemic
began. By that time, the plant had been shut down and some of the equip-
ment had been removed from the plant. Hearing, supra note 1, at 252 (mem-
orandum from Ronald F. Tetzlaff et al. to Richard R. mlug (June 29, 1990)).
' Gibbs & Mackler, supra note 258, at 212 (1987). The FDA requires
product literature to be included with all prescription drugs. This information
is used "to allow the physician to make an informed risk/benefit assessment
for the individual patient, to inform the patient of what risks a product may
have, and to reduce the risks of using the product." There are three basic
sources of this information. First, it must be included as a package insert
with the product. Second, the Physician's Desk Reference contains product
labeling for approved products. Third, any advertisements for prescription
drugs must contain a summary of product information. Id. at 212-13.
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relieves heartburn. However, if fifty percent of those taking
amino acid X experience mild nausea from taking it, consumers
have a right to be told.
(7) The FDA should conduct random testing of dietary
supplements for contamination
At random intervals, the FDA should test supplements for
contamination. If the supplements exhibit unacceptable impuri-
ties, the FDA should fine the manufacturer and, in the case of
repeat offenders, recall the product pending FDA review of the
manufacturing process. This would encourage manufacturers to
control strictly the quality of their products and to monitor
continually the safety of their products.
CONCLUSION
Protecting consumers' rights to choose health-related prod-
ucts is a noble goal, but protecting the consumers' health is
paramount. With new scientific advances in medical manufac-
turing technology taking place at a breathtaking rate, it is of
the utmost importance to protect an uninformed public from the
hidden risks that lurk in products found on the shelves of local
health-food stores. Manufacturers can and will take unjustified
risks with the public's health unless they are regulated strictly.
None of the three bills proposed in Congress give the FDA
enough regulatory power to keep the dietary supplement indus-
try from playing Russian roulette with the public's health. Both
the Health Freedom Act of 1993 and the Dietary Supplement
Health and Education Act sacrifice consumer safety for consum-
er choice. The Dietary Supplement Consumer Protection Act,
although more consumer-protective than the other bills, still
fails to accord the consumer adequate safeguards.
Regulating dietary supplements as drugs will assure con-
sumer safety and might produce other benefits. Regulation
might motivate pharmaceutical companies to research these
amino acids and discover safe, effective, and health-improving
uses for them, without fear that supplement manufacturers will
appropriate their expensive research and produce inexpensive
supplements. Consumer choice may suffer slightly from dimin-
ished access to supplements, but the gains in consumer safety
outweigh the costs of requiring consumers to purchase a drug
rather than an unregulated dietary supplement. However, since
Congress and the FDA have refused to seriously consider the
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option of regulating amino acids as drugs, the regulatory
scheme Congress enacts should be strict and well-enforced,
placing the health of the American public above the pecuniary
interests of the supplement manufacturers.
If the U.S. fails to take any action to regulate amino acid
manufacturers, additional crises will certainly arise. Some-
where a contaminant will slip into a manufacturing process and
became part of a gelcap. People will take amino acids in toxic
doses in light of publicized reports that they prevent certain
illnesses. Combinations of amino acids will result in unintend-
ed drug interaction because the potential for such problems was
never adequately studied before sale. It is not a matter of if,
why, or how. If amino acids remain unregulated, it is only a
matter of when.
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